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 This thesis is concerned with the development of methods by which to access 
compounds possessing the 3,4-cyclopropane-annulated 1,5-diazocin-2-one scaffold. The 
methods described herein are based on the intramolecular nucleophilic addition of nitrogen 
nucleophiles to the cyclopropene double bond in a direct 8-membered cyclization. This 
method allows for access to previously-unknown diazocines of their type – namely, 1,5-
diazocin-2-ones possessing fusion to a cyclopropane moiety. The described method allows 
for potential diversification of the cyclic products via a modular approach to the linear 
precursors which affords the possibility to easily explore new chemical space by the 
variation of simple building blocks.  
 Chapter one provides a review of the known methods by which to synthesize 1,5-
diazocin-2-ones. The chapter begins by highlighting the importance of members of this 
class of molecules as effective pharmaceutical agents and as drug candidates. Synthetic 
methods involving the direct 8-membered cyclization of linear precursors are then 
discussed – as well as their modes of activation. Furthermore, synthetic approaches to the 
scaffold by cycloaddition, transition metal-catalyzed tandem reactions, multicomponent 
reactions, and various rearrangements and fragmentations are discussed. 
 Chapter two describes the development of a synthetic pathway to the direct 
precursors to the cyclopropane-annulated 1,5-diazocin-2-one scaffolds that are the targets 
of the efforts of this project. Synthetic strategies are developed and improved upon in order 
to afford substrates that are relatively easy to construct and assemble in a modular fashion  




so as to provide easy access to a plethora of new compounds having potentially interesting 
bioactivities.  
 Chapter three focuses on the strain release-driven cyclizations of the previously 
described precursors to afford the diazocinone scaffold of interest. The optimization of the 
reaction and tolerance of the method to the electronic nature of the various nucleophiles 
employed is discussed. This method is one requiring mild conditions by taking advantage 
of the high energy and electrophilicity of the cyclopropene moiety. Several novel 
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Chapter 1. The Synthesis of 1,5-Diazocin-2-ones 
1.1 Introduction 
Prior to the late 1960’s, the 1,5-diazocin-2-one moiety (Figure 1) had received no 
attention from the synthetic community.1 Compounds based on the homologous  
7-membered scaffold (e.g. benzodiazepines) had already received much attention due to 
their then-newly discovered effects on the central nervous system of mammals where they 
were found to be potent anticonvulsive agents,2 tranquilizers,3 anxiolytics,4 muscle 
relaxants,5 and antiepileptics.6 The wide range of biological importance of compounds 
possessing this 7-membered azalactam moiety sparked curiosity about whether the 8-
membered homologues of such systems might exhibit similar, greater, or otherwise 
interesting biological activity. Over the decades following, interest in synthesizing these 
scaffolds grew ever more rapidly. A plethora of diverse synthetic pathways to novel 1,5-
diazocin-2-ones emerged; and with them, structure-activity relationship studies confirming 
the biological importance of these molecules. 
1.2 Nomenclature 
The nomenclature, terminology, and numbering used in describing 8-membered 
azalactams such as 1,5-diazocinones is not highly uniform throughout the literature. As is 
the case with much of chemical nomenclature, certain names may refer to a very specific 
set of chemical species, while the very same name may be used elsewhere in the chemical 
literature in a more inclusive manner – sometimes referring to a large set of structures 
which all possess some common feature. The nomenclature surrounding azalactams is, at 
very least, less than perfectly conducive to understanding and clear communication. In 
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order to inoculate the reader against confusion and ambiguity, the nomenclature of so-
called “diazocinones” in the context of this thesis will be discussed at the outset.  
 
Figure 1: The 1,5-diazocine-2-one moiety alongside other diazocines. 
This thesis is concerned with the synthesis of compounds possessing the 1,5-diazocin-2-
one moiety; an 8-membered ζ–azalactam motif (Figure 1). Throughout this work, any 
chemical species containing this moiety may be referred to generally as a diazocinone, or 
even more generally – when the context is deemed to be clear – as a diazocine. The term 
diazocine refers to any 8-membered cycle with six carbon atoms and two nitrogen atoms – 
whether or not it contains a carbonyl. The term diazocanone refers more specifically to 
diazocinones for which there is no unsaturation within the 8-membered ring itself. The 
terms that are used in this work have been chosen carefully with context and clarity as the 
guiding principles. 
1.3 Occurrence in Nature and Biological Activity 
Compounds containing the 1,5-diazocin-2-one moiety have scarcely been observed 
in nature.7 Despite this, there has been a longstanding and consistently active synthetic  


































(-)-(S,S)-homaline (1) (-)-(R,R)-hopromine (2)
(-)-(4'S,4''R,2'''R)-hopromalinol (4)(-)-(R,R,R)-hoprominol (3)
 
Figure 2: The four naturally-occurring members of the homalium alkaloid family. 
interest in members of the naturally-occurring homalium alkaloid family (Figure 2). The 
four known naturally-occurring homalium alkaloids were isolated in the 1970’s from the 
leaves of Homalium pronyense Guillaum – a plant species native to the forests of New 
Caledonia where it was first discovered. Though almost nothing is actually known about 
the true biogenesis of the homalium alkaloids, it often speculated that the alkaloids are 
biogenically-derived from spermine and the appropriate α,β-unsaturated fatty or cinnamic 
acids.7,8 These unique bis-azalactams have been the targets of many synthetic efforts over 
the past three decades.7 
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Figure 3: Drug candidates possessing the 1,5-diazocin-2-one moiety. 
The 1,5-diazocin-2-one core is present in many potential and actual therapeutic 
agents (Figure 3). The diazocan peptomimetic 5 exhibits high levels of activity as a 
selective caspase-1 inhibitor (Casp-1 IC50 = 19 nM, THP-1 IC50 = nM); a relatively new 
class of pharmaceutical agents which are effective in the treatment of rheumatoid arthritis 
and, in addition, have shown promising anti-inflammatory and analgesic activity in animal 
models.9,10 
The compound SM-337 (6) belongs to a family of conformationally-constrained 
mimetics of the endogenous IAP antagonist Smac (second mitochondria-derived activator 
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of caspases). Over the past decade, Smac mimetics have garnered increasing attention 
showing great potential as a new class of antitumor drugs. Compound 6 exhibits high 
potency as a cell growth inhibitor (IC50 = 31 nM) and in inducing apoptosis (100 nM, 24 
h) in the MDA-MB-231 cancer cell line. This, coupled with its high oral bioavailability 
and excellent solubility in aqueous media, have prompted further optimization as well as 
in vivo testing.11 A related compound (7) possesses the same 8,5-fused core as SM-122, 
but is joined to an identical unit via an acylated 4-phenylenediamine linker. Because of this 
two-unit structure, 7 is in a class dubbed “bivalent” Smac mimetics. Like its monovalent 
analogs, SM-1200 is designed to act as an IAP antagonist. Excellent levels of cell growth 
inhibition were observed in both MDA-MB-231 breast cancer (IC50 = 11.0 nM) and SK-
OV-3 ovarian cancer (IC50 = 28.2 nM) cell lines. In vivo studies in mice impressively 
showed rapid and complete tumor regression. With the administration of 12 mg/kg per 
week for 4 weeks, 99% tumor regression was achieved in seven mice while six of the seven 
mice remained tumor-free for 27 days following the final dose.12  
1.4 Synthetic Approaches Toward 1,5-Diazocin-2-ones 
Medium-sized rings – and 8- to 10-membered rings, in particular – are difficult to 
synthesize via conventional methods of cyclization.13 This is due in large part to the 
enthalpy cost incurred in the transition state as well as the increased enthalpy of the cyclic 
products relative to their linear precursors.14 The effective synthesis of 8-membered 1,5-
diazocin-2-ones via direct cyclization has been accomplished in some cases. This difficulty 
has stimulated the development of alternative methods for accessing the scaffold  
(Figure 4). 
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Figure 4: Several synthetic approaches to the 1,5-diazocin-2-one scaffold. 
The rearrangements of existing ring systems, transamidative ring expansion, multi-
component tandem reactions, and several other efficacious methods have emerged from 
these efforts. The remainder of this chapter provides an account of the conventional, as 
well as the more exotic, methods for the preparation of molecules containing the 1,5-
diazocin-2-one moiety.   
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1.5 Direct 8-Membered Ring-Closure via Intramolecular Acylation of Amines 
Accessing ζ-lactams and ζ-azalactams via 8-membered cyclization is often 
problematic due to the unfavorable enthalpic and entropic factors which do not plague 
systems of smaller (4-, 5-, and 6-membered), or in fact larger (12-membered and larger) 
size.15 Though direct 8-membered cyclization could be considered the most 
straightforward route toward these heterocycles, it represents only a small portion of the 
published syntheses of 1,5-diazcin-2-ones.  
1.5.1 Intramolecular Acylation of Amines 
The successful direct 8-membered intramolecular acylation of amines to provide 
1,5-diazocin-2-ones has been achieved in some cases. The success of these reactions varies 
greatly with varying substrates, and substrates often exhibit a strong or exclusive 
preference for a particular set of reagents and/or other conditions. Commonly employed 
reagents such as DCC, CMPI, thionyl chloride, the BOP reagent, and TBTU have all been 
shown to be effective in some cases – though no general conditions have been identified 
which are successful in general for the transformation.16,17 
Activation of Carboxylic Acids 
 The activation of a carboxylic acid function toward intramolecular nucleophilic 
attack by an amine nitrogen is a common strategic starting point for the formation of 8-
membered nitrogen heterocycles. A small number of examples are present in the literature. 
 In an effort to synthesize pharmacologically relevant homologues of then-recently 
reported potent CNS depressants of the benzodiazepine family, Aiello et al. prepared fused 
3-ring 1,5-diazocenes 10 via activation of the carboxylic acid function of biaryl anilines 9 
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with thionyl chloride in good yields (Scheme 1).18 To the knowledge of the author, this is 
the only report of a successful synthesis of 1,5-diazocin-2-ones employing thionyl chloride 
as a reagent for carboxylic acid activation. 
Scheme 1 
 
In 2008, Stansfield et al. reported the synthesis of tetracyclic indole 15 as a potential 
inhibitor of hepatitis C virus NS5B polymerase. Building upon a substituted indole 
scaffold, diazocine 15 was realized via late-stage 8-membered cyclization (Scheme 2).  




Activation of the carboxylic acid function of ζ-amino acid 14 was facilitated by peptide 
coupling reagent TBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate). Direct 8-membered cyclization via nucleophilic attack of the aniline 
nitrogen on the activated acid function provided benzodiazocine 15.19 
 Alkoxide-promoted intramolecular nucleophilic attack of amines on carboxylic 
esters to furnish ζ-lactams and ζ-azalactams is a known (albeit scarcely reported). While 
this chemistry is routinely employed in the conversion of esters to amides, in the context 
of the synthesis of 1,5-diazocin-2-ones it has not been successful. In an effort to synthesize 
saturated 7-amino-1,5-diazocinone 18, Hirokawa et al. attempted the cyclization of 
protected amino ester 16 via Boc-deprotection with trifluoroacetic acid followed by 
treatment with sodium methoxide (Scheme 3). These conditions failed to provide the 
product. Aqueous hydrolysis of the ester function of 16 with sodium hydroxide and 
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subsequent treatment of the resulting amino acid (17) with the BOP reagent furnished the 
saturated chiral diazocine 18 in nearly quantitative yield.16  
Scheme 3 
 
Azalactams containing no unsaturation in, or ring fusion to, the 8-memebered ring 
are generally considered to be greater synthetic challenges than their unsaturated 
counterparts as their linear precursors exhibit more degrees of freedom resulting in the 
amplification of unfavorable entropic factors of medium-sized ring closure.20 This example 
of the cyclization of a saturated 1,5-diazocin-2-one 18 shows the BOP reagent to be 
effective, albeit in just a single case. 
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Metal-Templated Intramolecular Acylation 
With the total synthesis of spermine alkaloids (–)-(R,R)-hopromine (2) and (±)-
homaline (1) by Hesse et al. in 2002, a novel path to optically-active 1,5-diazocan-2-one 
cores was established via an antimony-templated cyclization (Scheme 4). Chiral N-
sulfonyl-protected β-amino esters 19 were alkylated at the sulfonamide nitrogen with N-
Boc-protected 1-iodopropylamine and subsequently converted into the corresponding free 
chiral amines 20 using trifluoroacetic acid.  In screening conditions for the cyclization of 
ζ-amino esters 20, the commonly-employed peptide coupling systems DCC/DMAP, 2-
chloro-1-methyl-pyridinium iodide/Et3N, and DPS, as well as mixed anhydride systems 
Scheme 4 
 
all proved ineffective in accomplishing the transformation. Despite the risk of forming 
undesired dimerization products, a metal-templated cyclization using triethylstibenite was 
attempted and afforded the diazalactams 21 in very good yields.17 This method has since 
been utilized in the asymmetric synthesis of the homalium alkaloid (R,R,R)-hoprominol by 
Hesse et al.21 
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The first successful asymmetric synthesis of natural homalium alkaloid (S,S)-
homaline (1) was undertaken in 2012 by S.G. Davies et al. making use of triethylstibenite 
to promote the key 8-membered cyclization step (Scheme 5). 
Scheme 5 
 
 Chiral amino ester 24 was accessed via a highly diastereoselective 1,4-addition of 
enantiomerically-pure secondary lithium amide 23 to (E)-methyl cinnamate which 
proceeded with >99:1 diastereoselectivity. Sequentially, removal of the N-α-methyl-p-
methoxybenzyl group with trifluoroacetic acid, reductive methylation with 
paraformaldehyde and sodium cyanoborohydride, and conversion of the primary chloride 
into a primary azide with sodium azide afforded 25 in 69% yield over three steps. A 
Staudinger reduction followed by treatment with triethylstibenite at elevated temperatures 
provided ζ–azalactam 27 in 62% yield over two steps.22 Also in 2012, the same group 
reported the first asymmetric synthesis of natural homalium alkaloid (–)-(R,R)-hopromine 
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(2) employing the same methodology and starting from chiral amino ester 24. In exploring 
alternative routes to the target, it was found that the metal-templated cyclization step fails 
if the amine nucleophile 26 is modified to be secondary (N-allyl) rather than primary. The 
cyclization also fails if the electrophilic component is a tert-butyl ester rather than a methyl 
ester. These two observations suggest that the antimony-templated cyclization is sterically 
sensitive.23  
In yet another report from 2012, S.G. Davies et al. reported the total syntheses of 
(–)-(R,R,R)-hoprominol (3) and (–)-(4ʹS,4ʹʹR,2ʹʹʹR)-hopromalinol (4). With modifications 
to the substituent at the 4-position of α,β-unsaturated ester 22, the requisite 1,5-
diazocanone units required for these syntheses were assembled using the same 
methodology.24 
1.5.2 Decarboxylative Photocyclization 
Griesbeck and co-workers reported a novel synthetic approach to synthesizing 1,5-
benzodiazocines 31 in addition to homologous compounds ranging in ring size from 9–16 
members depending on the length of the alkylcarboxy tethered to the benzamide nitrogen 
(Scheme 6). Decarboxylative intramolecular photocoupling was accomplished in water-
acetone (1:1) under a nitrogen atmosphere at 15 °C while irradiated with 300nm light 
produced from a low pressure phosphor-coated mercury lamp. A decarboxylated anionic 
biradical 30 was generated and carbon-carbon bond formation between the two radical 
centers shown was successfully facilitated. The product distribution was that the primary 
species obtained was the desired benzodiazocine 31 and that the major side product was 
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that of so-called “simple” carboxylation, forming uncyclized 32. The chemical yield of this 


































a: R = H










32b, not reported  
 
1.5.3 Intramolecular Nucleophilic Aromatic Substitution 
In the preparation of potent NK1 antagonists, Seto and co-workers constructed 1,5-
diazacanone 36 which served as a point of divergence from which the targeted bioactive 
azalactams could be prepared (Scheme 7). Condensation of 4,6-dichloro-2-
(methylthio)pyrimidine-5-carbonyl chloride (33) with differentially bis-substituted 1,3-
diaminopropane 34 followed by removal of the Boc protecting group in acidic ethanol 
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delivered compound 35; the immediate precursor to cyclization. Direct 8-membered 
cyclization was accomplished via intramolecular nucleophilic aromatic  
Scheme 7 
 
substitution within pyrimidine 35 consisting of the displacement of chloride by the primary 
amino tether situated ortho to the CAr-Cl bond via SNAr afforded bicyclic azalactam 36. No 
purification was performed during this sequence until isolation of 36 was performed after 
which the product was obtained in 81% overall yield.26  
1.5.4 Intramolecular Reductive Alkylation 
In 2006, Wang et al. employed synthesized conformationally-constrained reverse-
turn mimetic 40 using late-stage direct 8-membered cyclization to access the  
1,5-diazocinone moiety (Scheme 8). The 2,5-disubstituted pyrrolidine 38 was obtained via 
modification of the naturally-occurring amino acid derivative in eight steps. The secondary 
pyrrolidine was then converted to tertiary amide 39 via peptide coupling with  
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Z-3-(Boc-amino)-L-alanine followed by deprotection of the primary alcohol and its 
subsequent oxidation with Dess-Martin periodinane.27 
Scheme 8 
  
In the key ring-forming tandem sequence, palladium-catalyzed hydrogenative 
conditions were employed wherein reductive Cbz-deprotection occurred, exposing the 
primary amino group which was then poised for condensation with the nearby aldehyde 
group. The corresponding imine was readily reduced under these hydrogenative conditions 
to furnish the product (40) in 64% yield.27 Over the course of time of 2008 to 2012, Wang 
et al. employed this synthetic method to build up several libraries of potent Smac mimetics 
for SAR studies.11,28–30 as well as in the synthesis of effective conformationally-constrained 
peptidomimetic STAT3 inhibitors.31 The aforementioned “bivalent” Smac mimetic SM-
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1200 (Figure 3, Compound 7) was synthesized by Wang et al. employing this same 
methodology.12 
1.6 Fragmentation of 1,5-Bridged 1,5-Diazocin-2-ones 
In the first ever reported synthesis of a 1,5-diazocinone in 1969, Denzer and Ott 
successfully accessed the 8-membered scaffold via twisted amides 42 (Scheme 9). The 
featured bridged bicyclic species was obtained via the intramolecular acylation of the 
nitrogen at the 1-position by the β-amino acid tether extending from the nitrogen at the 
Scheme 9 
 
5-position of compounds 41. Subsequent treatment of 42 with dilute hydrochloric acid at 
room temperature produced benzodiazocines 43 in very good to nearly quantitative yields. 
In the very same publication, it was reported that the methylene bridge of twisted amide 
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42a could be cleaved under hydrogenative conditions using Adams’ catalyst to afford the 
corresponding 5N-methylated analog of 44 (Scheme 9).1  
1.7 Transamidative Strain-Release Driven Ring-Expansion 
The difficulty of the direct cyclization of 1,5-diazocin-2-one ring systems lead to 
the use of alternative forms of activation to gain access to the ring system. Rather than 
promoting the cyclization via the activation of one of the functionalities with a chemical 
agent during the ring forming step, strain energy release has also been employed.  
Crombie and Jones et al. developed a strain release driven reaction to form saturated 1,5-
diazacan-2-ones 47 as well as their 7- and 9-membered homologues (Scheme 11). The 
treatment of brominated azetidines 45 with a primary amine in a sealed reaction tube for 
2–7 days facilitated nucleophilic substitution to generate N-aminoalkylazetidinone 
intermediates 46. The strain energy of the geometrically-constrained 4-membered azacycle 
provided the thermodynamic driving force for intramolecular transamidative ring-
expansion to afford products 47. For yields shown in Scheme 10, the reaction was carried 
out without isolation of the N-aminoalkylazetidinone intermediates 46. However, by 
stopping the reaction during its normal course, the isolation and structure elucidation of 
intermediates 46a and 46b was possible – evidence that the reaction proceeds via an 
intramolecular transamidation.32 This method has since been used in the synthesis of 
natural homalium alkaloids (±)-dihydroperiphylline,33 racemic as well as (–)-homaline,34 
(±)-hopromine, (±)-hoprominol, (±)-hopromalinol,35 as well as unnatural analogs8 of the 
homalium group of alkaloids.  
 





 Pauls and Ramnauth et al. employed an intramolecular transamidative strategy in 
the synthesis of FabI inhibitor candidate 50 (Scheme 11). Upon hydrogenation of nitrile 48 
with hydrogen gas using palladium on carbon as the catalyst in the presence of acetic acid, 
spontaneous transamidation occurred forming intermediate 49 in the synthesis of oxindole-
containing species 50 – although no yield was reported.36 
Scheme 11 
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1.8 Beckmann Rearrangement of 4-Azepinone Oximes 
Fused tetracyclic isoindolodiazocinones 53 were found by Decroix et al. to be 
accessible from 4-azepinones 51 via the Beckmann rearrangement (Scheme 12). 
Azepinones 51 were converted into the corresponding oximes 52 via the treatment with 







































Oximination provided a mixture of configurational isomers with the anti isomer (i.e. with 
the hydroxyl group of the oxime further rather than nearer to the thiophene ring) 
dominating in every case. After only very coarse purification, the mixtures were heated in 
polyphosphoric acid for 45 minutes to provide the desired diazocines 53. It is worth 
noticing that in the cases of 52a and 52c, both the syn and anti oximes were converted to 
the desired 1,5-diazocenes 53a and 53c in excellent yields with no observed 1,4-diazocine 
54. On the other hand, the mixture of anti and syn oximes 52b led to the 1,5-diazocine and 
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the 1,4-diazocine, respectively. This suggests that, in the cases of 53a,b, the syn oximes 
undergo isomerization into the anti oximes prior to the rearrangement. This is not the case 
for the oxime mixture 53b.37 
1.9 Reductive N-N Bond Scission  
One strategy for accessing the 1,5-diazocinone moiety is to first construct a 1,5-
diazabicyclo[3.3.0]octan-2-one which is poised for reductive cleavage of the N-N double 
bond; effectively destroying the 1,5-fusion to unveil the 8-membered moiety. This 
approach offers the advantage of the relative ease with which 5-membered rings can be 
cyclized versus cyclizations to afford 8-membered cycles.38 
The first such reported method was toward the end of synthesizing chiral 
polyamines designed to bind to the vanadate anion (VO43-) to form functional mimics of 
the marine algae vanadium haloperoxidases (Scheme 13).38 
Scheme 13 
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The coupling of two N-Boc-protected serine units 55 to a single hydrazine unit 
yields diacylhydrazide 56 in moderate yield (65%). Conversion of the alkyl hydroxyl 
groups to chlorine in situ and subsequent intramolecular alkylation was accomplished via 
classical Appel reaction conditions to give the chiral 1,5-diazabicyclooctanone 57. An 
unprecedented selective monoreduction employing BH3ꞏTHF followed providing the key 
intermediate 58 in moderate yield (55%). The Boc protecting group proved to be less than 
completely stable to the reaction conditions for this reduction. The addition of Boc 
anhydride to the reaction mixture after quenching borane was essential to “reprotect” any 
naked amino groups. The facile cleavage of the nitrogen-nitrogen bond was accomplished 
with Raney nickel providing diazocine 59 in excellent yield.38 
Oppong et al. employed this method in an effort to synthesize a small library of 
potential ICE inhibitors for SAR studies (Scheme 14). Also starting from Boc-L-serine, 
EDC coupling with pyrazolidine followed by intramolecular Mitsunobu reaction produced 
intermediate 61. As with the synthesis of compound 59, treatment with Raney nickel was 
effective in cleaving the central N-N bond and furnishing diazocanone 62; the basis 
scaffold from which targets 63 were assembled. No chemical yields of ICE inhibitor 
candidates 63 were reported.9 




The first synthesis of unsubstituted 1,5-diazocan-2-one (65) was realized when 
prepared as an intermediate en route to simple mono-protected 1,5-diazacyclooctane 66 
(Scheme 15). The cleavage of the N-N bond was accomplished in high yield using Raney 
nickel. The successful synthesis of 66 established a novel route to differentially-protected 
1,5-diazacyclooctanes via the 1,5-diazocan-2-one moiety.39 
Scheme 15 
 
 Ukaji et al. reported on the desymmetrization of 1,4-pentadien-3-ol (67) in the 
synthesis of optically active 1,5-diazabicyclooctanones via asymmetric 1,3-dipolar 
cycloaddition; the products of which could then be converted to the corresponding 
diazocanones (e.g. 70) via reductive cleavage of the N-N bond (Scheme 16). This proceeds 
via a magnesium-mediated multinucleating chiral reaction wherein pentadienol 67 and 
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azomethine imines 68, and (R,R)-diisopropyltartrate – upon treatment with 3 equivalents  
of methylmagnesium bromide – form a coordination complex in which the chiral tartrate 
serves as a highly effective chiral auxiliary. The cycloaddition afforded the product 69 in 
modest yield and 98% enantiomeric excess. Reductive scission of the N-N bond with 
Raney nickel afforded diazocanone 70 – containing three new stereogenic centers – in 88% 




In a subsequent 2017 report, Ukaji et al. applied their previously-developed 
conditions to alcohol substrate 71 which provided optically active 1,5-
diazabicyclooctanone 72 in moderate yield and high enantioselectivity (Scheme 18). 
Having made use of (S,S)-DIPT, product 72 possessed the opposite sense of chirality than 
that of product 69 from the initial 2014 report described above (Scheme 16). Electing to 
cleave the N-N under dissolved alkali metal conditions with sodium in liquid ammonia 
after silyl protection with tert-butyldimethylsilyl chloride, diazocanone 73 was furnished 
in good yield.41 




1.10 Addition of Ureas to Arynes 
In 2002, T. Hiyama et al. reported the novel, regioselective insertion of arynes into 
the more common N-CO bond of ureas (Scheme 18). Aryne equivalents 74 were subjected 
to fluoride in order to induce 1,2-elimination to form the reactive intermediates 75. Before 
the early 2000’s, the addition of a nucleophile single-bonded to an electrophile (with the 
exception of a proton as the electrophile) across the aryne triple bond was generally 
possible only in the case of species containing specially-activated Nu-E bonds (e.g. Te-Te, 
S-S, C-Si, and C-Sn).  




Treatment with N,N'-dimethylpropyleneurea (DMPU) provided benzodiazocines 76 in 
moderate yield. Compounds 76 were formed with perfect regioselectivity, with the amide 
function placed at the more sterically congested site. The remarkably mild conditions, 
relatively low cost of reagents, and low step-count make this an attractive method for 
accessing the 1,5-benzodiazocine core.42  
Pyridines were employed as aryne (i.e. pyridyne) precursors by Sato et al. in 2013 
in the synthesis of bicyclic pyridines analogous to benzodiazocines 37 (Scheme 19). The 
methodology is essentially the same, using cesium fluoride at room temperature to generate 
pyridynes from silyl-protected pyridine triflates 77 to react subsequently with N,N'-
dimethylpropyleneurea (DMPU) affording fused bicyclic diazocinones 79 in moderate 
yield. Reaction of pyridine 77a with DMPU was only slightly regioselective, providing a 
distribution of products 79a and 80a in a 60:40 ratio. Reactions of the isomeric methoxy-
substituted pyridines 77b-c each afforded a single regioisomer in moderate yield.  




The incorporation of the methoxy group imparted to the reaction a strong regiochemical 
preference for a 1,3-relationship between the methoxy-bearing carbon and the carbonyl 
carbon. I.e. a strong preference exists for the diazocinone product with the least steric 
congestion near the aniline nitrogen. This is in keeping with the rational that the first step 
in the cyclization sequence is the nucleophilic attack of the urea nitrogen on an aryne 
carbon. This attack occurs at the least sterically hindered position.43  
In a 2015 report by Daugulis et al., a variation on aryne precursors for the formation 
of 1,5-diazocin-2-ones was presented. The traditional triflate leaving group was replaced 
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with bromide – and in one example, a sulfamate – while cesium fluoride was replaced with 
tetramethylammonium fluoride.  
Scheme 20 
 
 From precursors 81, arynes of type 82 were generated in situ and the subsequent 
reaction with DMPU to afford provided benzodiazocinones in yields comparable to earlier 
reported reactions employing triflates (Scheme 20). Also in keeping with previous findings, 
the reaction exhibits a strong regiochemical preference for products with the least steric 
congestion near the aniline nitrogen.44 
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1.11 Intramolecular Azide-Alkyne Huisgen Cycloaddition 
The year 2010 saw two independent reports of the unprecedented use of Huisgen 
dipolar cycloaddition to furnish 1,2,3-triazole-fused benzo[1,5]-diazocinones – a unique 
diazocinone scaffold; the likes of which had been hitherto absent from the chemical 
literature. 
In an unprecedented route to molecules possessing the 1,5-diazocin-5-one moiety, 
Majumdar et al. reported the synthesis of 1,2,3-triazole-fused dibenzo[1,5]-diazocinones 
86 via an intramolecular Huisgen [2+3] cycloaddition (Scheme 21). Cycloaddition 
precursors 85 were prepared in good yields via acylation of 2-(phenylethynyl)anilines 84 
with 2-azidobenzoyl chloride. Over the course of five hours, the subsequent cyclization 
proceeded smoothly for all substrates 76 at 120 °C to furnish the products 86 in excellent 
isolated yields. Variation of R and/or Ar groups did not majorly affect the yields of azides 
85 nor their corresponding cyclized products (86).45 
 




In a separate and independent instance in 2010, Chowdhury et al. reported the 
synthesis of a collection of similar 1,2,3-triazole-fused benzo[1,5]-diazocinones 89 
(Scheme 22). The 1,2-substituted benzene rings 87 were prepared as anilines (rather than 
as azides 85). In a single reaction vessel, diazotization of anilines 87 was facilitated by 
nitrous acid and, upon the addition of sodium azide, was subsequently converted into 
organic azide intermediate 88. Cyclization at elevated temperatures occurred to furnish 
diazocines 89 in a three step, one pot process.46 





With interest in 1,2,3-triazole-fused 8-membered heterocycles as bioactive 
molecules growing, in 2012 Chattopadhyay et al. directed their efforts toward the synthesis 
of chiral non-racemic molecules of these types, including the first example of a chiral 1,2,3-
triazole-fused benzo[1,5]-diazocinone (Scheme 23). Starting material α-D-glucofuranoside 
90 was, in sequence, N-nosyl-protected with nosyl chloride and N-methylated with methyl 
iodide. Selective conversion of the non-fused vicinal diol was accomplished with acetic 
acid at room temperature. The diol treated with sodium periodate and then Bestmann’s 
reagent to afford terminal alkyne 91 (45%, 5 steps) via Seyferth-Gilbert homologation. 
Removal of the nosyl protecting group with thiophenol followed by acylation of the amine 
nitrogen with 2-azidobenzoyl chloride provided cycloaddition precursor 92 (37%, 2 steps). 




Upon heating at 120 °C for 2h in dry dimethylformamide, intramolecular azide-alkyne 
Huisgen cycloaddition occurred providing chiral 1,2,3-triazole-fused 
furobenzodiazocinone 93 in good yield.47 
In 2016, Ballet and Jida et al. demonstrated an efficient route to conformationally-
constrained tricyclic 1,2,3-triazole-fused benzo[1,5]-diazocinones via a tandem Ugi-
Huisgen sequence (Scheme 24). The reaction of 2-ethynylaniline (94) with Boc-β-azido-
L-alanine, acetaldehyde, and tert-butyl isocyanide in methanol at room temperature 
afforded the Ugi product 95 as the direct precursor to 1,3-dipolar Huisgen cycloaddition 
which was facilitated by heating at 70 °C for 24 hours. The chiral 1,2,3-triazole-fused 
benzo[1,5]-diazocinone 96 was obtained in 77% yield. Despite stereoretention at C(3), 
stereocontrol at C(9) was not achieved.48 
 




1.12 Ugi Four-Center Three-Component and Subsequent Reductive Cyclization 
A tandem one-pot, three component Ugi reaction and subsequent reductive 
cyclization was developed by Chattopadhyay in 2012 for the synthesis of 1,5-
benzodiazocine-2-ones 101 (Scheme 25). β-Lactams 100 were formed at room temperature 
from isocyanates 97, β-alanine (98), and 2-nitrobenzaldehydes 99.  
Scheme 25 
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Poor yields were obtained when o-tolyl and 2-naphthyl isocyanates were used leading the 
authors to focus on aliphatic isocyanates. Several reagent systems, including zinc metal 
and also tin in acetic acid, successfully reduced the nitro group. However, in these cases, 
the desired subsequent cyclization failed to occur. With its mild acidity and high functional 
group tolerance, Fe/NH4Cl was screened as a reducing agent and was found to allow for 
successful cyclization post-reduction. The placement of electron withdrawing groups on 
the aryl ring was found to increase the rate of the reaction significantly. Furthermore, 
higher yields were obtained when the isocyanate bore a cyclohexyl substituent as opposed 
to iso-propyl or tert-butyl substituents. It is reasoned that this is likely due to the cyclohexyl 
group being sterically smaller than the others. Performed in a one-pot, two-step fashion, 
diazocines 101 were provided with yields of 61-88%.49 
 
1.13 Ugi Four-Component Reaction and Subsequent Intramolecular SNAr 
Biron et al. reported in 2017 the two-step sequence of Ugi four-component reaction 
followed by nucleophilic aromatic substitution initiated by Fmoc-deprotection to afford 
bicyclic 1,5-benzodiazocin-2-ones 104 (Scheme 26). β-amino acids 102 reacted in a Ugi 
reaction with benzylamine, tert-butyl isocyanide, and 2-fluoro-5-nitro-benzaldehyde in 
methanol:dichloromethane (2:1) for 72 hours at ambient temperature to afford the expected 
Ugi products 103 in good yields.  



















a: R = H


















103c, 81% 104a, 69%, NA
104b, 44%, 2.3:1 dr
104c, 29%, 1:1 dr
 
Upon removal of the Fmoc protecting group with trifluoroacetic acid, nucleophilic 
displacement of the arene fluorine substituent occurred providing azalactams 104 with 
yields ranging from poor to moderate. The bicyclic products containing multiple 
stereogenic centers were obtained as mixtures of diastereomers. The diastereomeric ratios 
in the cases employing β-amino acids 102b and 102c, were 2.3:1 and 1:1, repectively.50 
 
1.14 Nucleophile-Induced Rearrangement of 9-Membered Ureas 
A novel method for accessing chiral, tetracyclic diazocinones 106 was reported by 
Jones and Westwood et al. in 2016 (Scheme 27). The method involves a rearrangement 
initiated by a nucleophilic attack of an alkoxide (or amine) on the urea carbonyl carbon  




C(16) of substrates 105. It is proposed that the nucleophilic attack causes subsequent ring-
opening via the cleavage of the C(16)-N(15) bond, forming an 11-membered macrocyclic 
intermediate. It is proposed that subsequent ring-closure via nucleophilic attack of N(15) 
on carbonyl C(9) takes place to afford the 5,8-fused system (i.e. compounds 106) from the 
starting [8.3.1]-bridged ring system of starting materials 105. Reactions with alkoxides 
proceeded rapidly (i.e. complete within 10 minutes) and with excellent yields (90-99%) 
while reactions employing amines as nucleophiles proceeded less rapidly (completion 
within 3 hours) and with much poorer yields (33–74%).51 
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1.15 Metal-Catalyzed Tandem Processes 
1.15.1 Palladium-catalyzed Domino Synthesis of Tetracyclic Diazocines 
In 2003, Zhu et al. disclosed a novel palladium-catalyzed domino process for the  
conversion of simple linear diamides 107 into the complex fused tetracycles 108 in a single 
reaction vessel (Scheme 28). The transformation consists formally of the formation of one 
CAr-CAr bond and one CAr-N bond accompanied by the instantiation of both a 6-membered 
Scheme 28 
 
and an (n + 5)-membered ring. It is speculated that the sequence is that of an intramolecular 
Buchwald-Hartwig amination followed by C-H activation and subsequent aryl-aryl bond 
formation. Although the reaction provided modest and very consistent yields for the 
tetracyclic fused lactams 108b, 108c, and 108d – corresponding to 9-, 11-, and 13-
membered azalactams, respectively – azalactam 108a (i.e. the product containing the 
relevant 1,5-diazocinone core) was obtained in much lower yield (18%).52 In a follow-up 
publication, further optimization of this reaction was attempted. It was found that diluting 
the reaction to 1 mM – versus the initially-reported 20 mM – improved yields in some 
cases although only by a small amount in the case of the 1,5-diazocinone.53 
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1.15.2 Copper-catalyzed Tandem Synthesis of Bicyclic Diazocines 
A one-pot tandem sequence to afford substituted benzodiazocines 112 was 
developed by Buchwald et al. and reported in 2004 (Scheme 29). The sequence is that of 
an Ullman-type coupling of unsubstituted and 4-substituted azetidinones 109 with 
bromobenzylamines 110 followed by intramolecular transamidation of intermediates 111 
























110 °C, 22 - 24h
109 110
111
a: R1 = H, R2 = H, R3 = H, R4 = H
b: R1 = Ph, R2 = H, R3 = H, R4 = H
c: R1 = H, R2 = Bn, R3 = R4 = OMe
d: R1 = H, R2 = (CH2)5OH, R
3 = H, R4 = H















group at the 4-position of the β-lactam was well tolerated as were N-benzylated and N-
alkylated bromobenzylamines. Yield suffered a significant amount with the use of a 
sterically-congested bromobenzylamine (110e).54  
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1.15.3 Palladium-catalyzed Tandem Synthesis of Indole-Fused Tricyclic Diazocines 
Q. Wang et al. reported in 2015 the development of a route to unique fused tricyclic 
diazocines (Scheme 30). Under moderate conditions, trifluoroacetyl-protected 2-
iodoaniline 113 undergoes a single-pot tandem reaction with terminal acetylene 114 to 
form 1,2-indole-fused diazocine 115 in moderate yield (61%). 
Scheme 30 
 
The authors reason that the reaction begins with the Sonogashira coupling of the two 
components, and proposed five different pathways are proposed the subsequent steps in the 
mechanistic sequence. Palladium acetate and triphenylphosphine form the catalyst while 
potassium carbonate serves as the base. The phase transfer catalyst tetrabutylammonium 
bromide (TBAB) was found to be essential to the proceeding of the reaction.55 
 
1.15.4 Copper-Catalyzed Ritter-Condensation-Hydroamination Process 
In 2017, Abe et al. reported the first synthesis of quinazoline-fused diazocines in a 
copper-catalyzed tandem process (Scheme 31). Aminobenzoic acids 116 reacted with 
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acrylonitrile (117) in the presence of copper(II) oxide and phosphorus oxychloride at room 
temperature to afford quinazoline-fused tetracyclic diazocines 120 in mostly modest yields.  
Scheme 31 
 
The authors propose a reaction pathway in which benzoic acid 116 reacts with acrylonitrile 
in a Ritter-type cyclization to afford intermediate 118 which then condenses with another 
equivalent of aminobenzoic acid 116 forming adduct 119 which undergoes intramolecular 
hydroamination to furnish the anti-Markovnikov product 120. Substitution at the aryl ring 
of benzoic acids 116 has the general effect of lowering the chemical yield of the product. 
Strong general trends based on steric and/or electronic effects were not observed. With the 
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introduction of a nitro group into the aryl ring, the desired product was not obtained and a 
complex mixture of products instead resulted.56 
 
1.16 Palladium-Catalyzed Carbonylative Cross-Coupling 
In a report by Tan et al. in 2017, the asymmetric total synthesis of natural 
arylquinazolinone-fused diazocine eupolyphagin (125) via axially chiral arylquinazolinone 
123 was described (Scheme 32). In the asymmetry-inducing step, phosphoric acid CP3 
was employed as a chiral Brønsted acid catalyst in condensation of benzaldehyde 122 with 
aminobenzamide 121 with subsequent dehydrogenation with 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ) to afford the axially-chiral arylquinazolinone 123 in an initial 
yield of 95%, but exhibiting an enantiomeric excess of only 58%. Recrystallization from 
dichloromethane/ethyl acetate afforded the material with an improved enantiomeric excess 
of 95% with a diminished yield of 44%. The high yielding (91%) removal of the Fmoc 
protecting group with piperidine was accomplished with no effect on optical purity to 
afford the immediate precursor to the formation of the diazocine core (124). Employing 
bis(dibenzylideneacetone)palladium(0) and dppp as the catalyst, compound 124 was 
treated with carbon monoxide in the presence of tetrabutylammonium chloride to effect a 
carbonylative Buchwald-Hartwig-type reaction,  




furnishing pentacyclic 1,5-diazocinone 124 in 95% yield and full retention of enantiomeric 
purity. Conversion of the methoxy group with boron tribromide delivered the natural 
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1.17 Conclusion 
Over the course of more than 50 years, many effective methods by which to 
synthesize 1,5-diazocin-2-ones have been developed which have produced a diverse set of 
members of the class. Many compounds possessing the unique structural core exhibit 
interesting biological activities warranting the further exploration of this still vastly 
unprobed chemical space. 
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Chapter 2. The Development of a Modular Synthetic Route to Synthetic 
Precursors to Cyclopropane-Fused 1,5-Diazocin-2-ones 
2.1 Introduction 
As described in the previous chapter, access to compounds containing the 1,5-
diazocin-2-one scaffold is highly desirable due their potential as important 
pharmaceuticals, yet the methodological avenues and functional group variability remain 
underexplored. Thus, new synthetic methods for accessing these species – as well as in 
gaining access to novel members of the class – are in demand. The diversity of available 
methods for their synthesis (discussed in Chapter 1) include the expansion, contraction, 
rearrangement, and fragmentation of existing ring systems, cycloadditions, transition 
metal-catalyzed tandem processes, and various multi-component reactions. Viable 
synthetic methods toward 1,5-diazocin-2-ones via direct 8-membered cyclization were also 
discussed along with various sources of activation by which the barrier to medium-sized 
ring closure to afford these compounds is surmounted.  
Recently in our labs, we have become interested in employing shelf-stable 3,3-
disubstituted cyclopropenes as energy-rich electrophiles to drive the cyclization of 
medium-sized rings and have demonstrated that such cyclizations can indeed be facilitated 
in the case of oxygen-based nucleophiles (Scheme 33).58  




The Rubin group next became interested in synthesizing cyclopropane-fused analogs of 
128 in which nitrogen nucleophiles were employed. Specifically, this thesis is concerned 
with the synthesis of 3,4-cyclpropane-fused 1,5-diazocin-2-ones 131 (Scheme 34). This 
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2.2 Reactivity Trends of Cyclopropenes Toward Nucleophiles 
The cyclopropene moiety is a highly-strained system due most primarily to the sp2-
hybridized carbons locked in an arrangement which constrains the carbocyclic bond angles 
to 60° – far from the ideal angle of 120°. This imparts an energy reserve of 53 kcal/mol.59 
This chemical potential energy can be used as a driving force for otherwise unfavorable 
chemical transformations.  
As a very energetic class of molecules, many cyclopropenes are unstable and 
difficult to obtain in isolated form (Figure 5). In the presence of nucleophilic species, 
cyclopropenes bearing electron-withdrawing substituents on one or both olefinic carbons 
(Figure 5, A, B) make excellent Michael acceptors and thus are highly unstable. Most 
 
Figure 5. The reactivity of various substituted cyclopropenes toward nucleophilic attack. 
conjugated cyclopropenes of this type are not isolable and must instead be generated in 
situ. The presence of alkyl, aryl, alkenyl, or alkynyl groups at C3 mitigates this to some 
degree (Figure 5, C). This stabilization is attributed to increased steric congestion and/or 
electron delocalization in cases of alkenyl, alkynyl, and aryl groups. Cyclopropenes 
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bearing an electron donating group at C1 or C2 (Figure 5, D) are stabilized compared to 
their EWG-bearing counterparts while 3,3-disubstituted cyclopropenes (barring the 
copresence of a C3-EWG) are among the most stable cyclopropene species (Figure 5, E, 
F),60 boasting shelf lives of several days, to months,61 and even years if stored at low 
temperature under nitrogen atmosphere.62  
 
2.3 Nucleophilic exo-trig Cyclization of 3,3-Disubstituted Cyclopropenes 
Though sufficiently stable if properly handled, the double bond of pre-generated 
3,3-disubstituted cyclopropenes remains highly electrophilic. Ring-retentive additions of 
oxygen-,63,64 sulfur-,65 phosphorus-,66 as well as carbon-nucleophiles67–70 to such substrates 
have all been reported. Rubin et al. recently disclosed a protocol for intramolecular exo-
trig cyclization via nucleophilic attack on cyclopropenes employing alcohols as 
pronucleophiles to afford 1,4-oxazepan-5-ones (7-membered) and 1,4-oxazocan-5-ones (8-
membered) species 128 in generally very good yields (Scheme 35).58  
Scheme 35 
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2.4 Addition of Nitrogen Nucleophiles to 3,3-Disubstituted Cyclopropenes 
Curious as to the reactivity of nitrogen nucleophiles toward nucleophilic 
cyclizations in analogous substrates, we subsequently began investigating the cyclization 
of nitrogen analogs of cyclopropenes 126 to form the corresponding cyclopropane-fused 
azalactams 131 (see Scheme 34 above). Earlier findings in the Rubin group demonstrated 
that 3,3-disubstituted cyclopropenes indeed undergo intermolecular nucleophilic addition 




However, it was observed that the amino-nitrogen of initial hydroamination product 133 
was sufficiently electron-donating so as to set up a highly polarized donor-acceptor 
cyclopropane (DAC) system with a high propensity for ring-opening, which occurred 
immediately. In the presence of a proton source, the resulting zwitterionic iminium 
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intermediate 134 then rapidly formed imine 135 (when R4 = H) or enamine 136 (when R ≠ 
H).71  
 With this in mind, it was imagined that intramolecular addition to such systems 
could be accomplished if the nucleophilic nitrogen center were sufficiently electron-
deficient so as to attenuate the DAC character of the resulting cyclic products, thus 
mitigating the tendency for ring opening. We directed our efforts toward the synthesis of 
3,3-disubstituted cyclopropene carboxamides, bearing an alkyl tether at the amide nitrogen 
which is terminated by an electron deficient nitrogen functionality, as precursors to 8-
membered cyclopropane-fused azalactams. Given the enhanced N-H acidity of 
sulfonamides relative to amines, as well as their known reactivity as good nucleophiles in 
the case of intermolecular addition to conjugated cyclopropenes,72 sulfonamide-terminated 
cyclization precursors of type 129 were targeted for synthesis (Figure 6). 
 
Figure 6: 3,3-Disubstituted cyclopropenes bearing a pro-nucleophilic sulfonamide functionality. 
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2.5 Synthetic Routes Toward 1,5-Diazocin-2-one Precursors 
For the synthesis of cyclization precursor cyclopropenes 129, a modular approach was 
desired in which various combinations of Ar1, Ar2, and R could be realized with relative 
ease by the simple variation of reagents employed in the construction of each building 
block. Intending to employ what has become a standard protocol73 in the Rubin group for 
the conversion of cyclopropene carboxylic acids 140 to amides, several potential synthetic 
































































































The construction of sulfonamidocyclopropene carboxamides 129 via Path A 
possesses the modular features desired. Secondary amine 139 would provide Ar2 which 
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could be introduced easily via the reductive alkylation of inexpensive 3-halopropylamines 
and subsequently acylated by cyclopropene carboxylic acids 140 (providing Ar1). The 
sulfonyl R-group would be born by sulfonamides 137 and incorporated via nucleophilic 
displacement of a leaving group (e.g. bromide) on the terminus of compound 138. This 
final step would very likely be problematic as the cyclopropene double bond is highly 
electrophilic and would likely participate in a competing nucleophilic addition under the 
necessary reaction conditions.  
 Path B, while retaining modularity, eliminates the problem of a difficult acylation 
step by introducing the R-bearing sulfonyl group by way of an electrophilic species (i.e. a 
sulfonyl chloride 141) so as to not to pose a threat to the fragile cyclopropene moiety. 
However, the acylation of cyclopropene carboxylic acid 140 is not likely to exhibit 
selectivity towards the secondary amino group over the primary amino group of mono-
alkylated 1,3-diaminopropane 143. Furthermore, the construction of mono-alkylated 1,3-
diaminopropanes 143 themselves presents a synthetic challenge that seemed best avoided. 
 The route to cyclization precursor 129 illustrated in Path C leaves the incorporation 
of the cyclopropene moiety until the final step, exposing cyclopropene carboxylic acid 140 
only to routinely-employed conditions which are preservative of the cyclopropene double 
bond. The challenge of efficient mono-functionalization of 1,3-diaminopropane – either by 
sulfonylation or alkylation – remains, in this case. With Path C also comes the potential of 
a low yielding and/or poorly chemoselective acylation of aminosulfonamide 144. High 
yielding, highly chemoselective acylations of secondary alkyl amines possessing primary 
sulfonamido groups have been reported with common reagents such as oxalyl chloride,74,75 
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EDC,76,77 and DCC;78 although such reports are quite scarce. Similar reactions exhibiting 
modest to low yields are similarly scarce75 and likely underreported as a result of their lack 
of utility. Bearing in mind the scarcity of reports and wide variation of success in the 
acylation of such compounds, as well as the challenges inherent to diamine mono-
functionalization, efforts toward the synthesis of building blocks 129 via Path C were 
undertaken.  
 
2.6 The Development of a Viable Synthetic Method Toward 8-exo-trig Cyclization 
Precursors 
We embarked on the forward synthetic plan shown in Scheme 38. We first sought 
a simple and high-yielding method – preferably requiring little to no preparative 
chromatography – for obtaining differentially-functionalized 1,3-diaminopropanes 144. 
 Scheme 38 
 
The high availability of reagents capable of installing tosyl (TsCl) and benzyl (PhCHO) 
functional groups led us to the choice of 1,3-diaminopropane 148 as a model differentially-
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functionalized diamine; to be synthesized via the mono-tosylation of 1,3-diaminopropane 





















with benzaldehyde and sodium borohydride (Scheme 39). Several attempts at the mono-
tosylation of 1,3-diaminopropane were all met with low isolated yield (18% maximum) – 
despite the adoption of reportedly successful methods79,80 from the literature. Mono-
alkylation of 1,3-diaminopropane employing a benzylhalide was not attempted as 
polyalkylation products would almost certainly be formed, and likely require column 
chromatography to obtain the desired material.81  We then began examining alternative 
pathways to compound 148 which to not require the mono-sulfonylation of 1,3-
diaminopropane. 
 Alkylation of p-toluenesulfonamide (TsNH2) with 3-bromopropionitrile resulted in 
a mixture of mono- and dialkylated products which could be separated via acid-base 
extraction, but afforded sulfonamide 149 in only modest yield. The following lithium 
aluminum hydride reduction of the cyano group of nitrile 149 provided amine 147 in low 
(30%) yield. The overall yield for the two steps was a mere 16% – less than the yield of 
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147, 30%  
 Highly efficient access to nitrile 149 was accomplished in two steps with an overall 
yield of 90% (Scheme 41). Bis-tosylation of 2-aminoethanol (151) simultaneously installed 
the desired terminal sulfonamide while converting the hydroxyl group into a sulfonate ester 
– providing an excellent leaving group for the subsequent step. Cyanide next displaced 
tosylate in a second high yielding step and required purification only in the form of 
filtration through a short plug of silica.  
Scheme 41 
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Reduction with LiAlH4 was attempted again in under various conditions on nitrile 149. The 
low yields of 20-30% were puzzling and it was thought that it might be the case that 
material was being lost in the work-up. Given the presence of both an acidic sulfonamido 
group and a basic amino group, the possible forms of N-tosyl-1,3-diaminopropane (147) in 
aqueous media were considered (Scheme 42).  
Scheme 42 
 
The reduction and subsequent workup was repeated multiple times employing adjustments 
in pH during workup, to no avail. The high solubility of 147 in water led us to attempt 
“water-free” quenches of the metal hydride reductions with hydrated pH-neutral salts such 
as sodium sulfate decahydrate so as to deprive the environment of a bulk aqueous medium 
for the desired compound to dissolve in. These efforts afforded no significant improvement 
in the yield of 147. 
 In pursuit of a method for the reduction of nitrile 149 which does not involve metal 
hydride reducing agents nor aqueous workup, attention turned to catalytic hydrogenation 
as a possible means of reduction. Adapting from a known procedure82 by Duggan et al., 
reduction over platinum(IV) oxide in the presence of chloroform afforded the desired 
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mono-tosylated amine as a hydrochloride salt in 93% yield (Scheme 43). Thus, amine 




Following the synthetic logic illustrated in Scheme 40, the benzylation of 147d was 
conducted via reductive alkylation with benzaldehyde followed by sodium borohydride 
employing triethylamine in order to allow for the formation of the free amine of 147d. The 
resulting yield was lower than anticipated, affording differentially-functionalized diamine 
148 with a yield of 25% (Scheme 44). 
Scheme 44 
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Despite the unsatisfactory yield, material was now in hand for the joining of this component 
and a cyclopropene carboxylic acid 149. The cyclopropene carboxylic acid bearing a 
phenyl group in the 3-position (i.e. Ar1 = Ph) was chosen. The reaction proceeded with a 
remarkably low degree of chemoselectivity; affording the acylated amine and the acylated 
sulfonamides in practically equal amounts and in very low yields (Scheme 45).   
Scheme 45 
 
Also somewhat remarkably, neither yield nor chemoselectivity changed significantly when 
EDC was employed as the amide coupling agent.   
While the acylation of amine 148 was found to give poor yield and selectivity in 
both cases, concurrently in our lab, tert-butyl carbamates 157 were being prepared with 
relative ease via the mono-Boc protection of 1,2-diaminoethane followed by reductive 
alkylation, and finally acylation (Scheme 46). Though the reductive alkylation of mono-
Boc-protected amine 155 exhibited low yield, the acylation of aminocarbamates 156 
proceeded with exceptional yield and with no chemoselectivity issues.  




This lead to the consideration of accessing sulfonamide-terminated cyclopropene 
carboxamide 129d via a homologous approach to that shown in Scheme 46 – using 
propylene diamine in place of ethylene diamine (Scheme 47). The introduction of the 




The mono-Boc-protection of 1,3-diaminopropane was much more successful than 
the previously discussed attempts at mono-tosylation. The borohydride reductive 
alkylation of mono-Boc-protected 1,3-diaminopropane 158 was as inefficient as the 
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homologous reductive alkylation of mono-Boc-protected 1,2-diaminoethane. Generally, 
the reaction sequence for synthesizing Boc-protected cyclopropene 160 (Scheme 47) 
afforded very similar results in each step for the synthesis of the homologous Boc-protected 
cyclopropene 157.  
The removal of the Boc group from cyclopropene 160 proceeded uneventfully to 
afford the ammonium trifluoroacetate (161) in high yield upon treatment with 
trifluoroacetic acid (Scheme 48). The subsequent tosylation of the amine nitrogen afforded 
the direct 8-exo-trig cyclization precursor in 85% yield.  
Scheme 48 
 
Though a successful synthesis of the desired cyclization precursor was achieved, 
the low efficiency (33% yield) of the reductive amination step still plagued the scheme. 
The success observed for nitrile reductions under hydrogenative conditions using a 
heterogeneous platinum catalyst (see Scheme 44 above) drew our attention to the 
possibility of performing the reductive amination entirely in a Parr type reactor using 
similar conditions. A search of the literature led to a 2008 report of a well-optimized, high 
yielding protocol of this sort. Hu et al. describe a “direct reductive amination” (DRA) of 
benzaldehydes.83 DRA is conducted under 1-2 atm hydrogen over palladium on carbon 
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using chloroform as an additive. The authors propose that chloroform undergoes a 
hydrodechlorination to afford hydrogen chloride which immediately poisons the ‘active 
palladium catalyst’, converting it into a species that is highly selective toward the reduction 
of imines in the presence of aldehydes. In addition, the generated HCl protonates the amine 
product allowing for easy isolation via filtration. Subjecting amine 158 to similar 
conditions afforded the corresponding amine hydrochloride in good yield – 82% compared 
to 33% with conventional borohydride reductive amination (Scheme 49). The reaction was 




It was also found that ammonium trifluoroacetate salt 161, although produced in 
high yield, started to exhibit signs of decomposition, in the form of a color change, within 
just a few hours after synthesis. Within 3-4 days, known reactions employing this material 
began to exhibit significant decreases in yield.  




For best results, the material was used immediately after its synthesis and concentration. 
In an effort to eliminate this problem, another avenue was explored for the Boc-
deprotection of cyclopropene 160. Known to be a suitable agent for removing Boc from 
nitrogen atoms, hydrogen chloride was considered. The bubbling of HCl gas through a 
solution of 160 in dichloromethane afforded, after a simple work-up, amine hydrochloride 
163 (Scheme 50). The salt was produced with a lower – although still satisfactory – yield 
and proved to be much more stable and also easier to work with. Compound 163 can be 
stored under no special conditions for many months without any noticeable degradation. 
Scheme 51 illustrates an effective synthetic pathway to cyclization precursors 129. 





2.7 Examples of Pronucleophilic 8-exo-trig Cyclization Precursors 
With a working method in hand for the synthesis of sulfonamide-terminated 
cyclization precursors of type 129, variation of the group R (i.e. sulfonyl group) was 
explored (Figure 7). Yields ranged from 55-88%, exhibiting no noticeable trend with 
respect to the electronic nature of the sulfonamides employed. Further, no trend with 
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A protocol for the synthesis of pronucleophilic 8-exo-trig cyclization precursors 
129 has been reported. Utilizing this approach, it is possible to synthesize a diverse range 
of cyclopropenes 129 featuring varying Ar1, Ar2, and R groups in many combinations by 
the use of 3,3-disubstituted cyclopropenes 140, 2° amine hydrochlorides 162, and sulfonyl 
chlorides 141 as building blocks. Several examples of compounds, in which the R group is 
varied, have been successfully synthesized and reported. The tolerance of this synthetic 
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2.9 Experimental 
2.9.1 General Information 
NMR spectra were recorded on a Bruker Avance DRX-500 (500 MHz) with a dual 
carbon/proton cryoprobe (CPDUL). 13C NMR spectra were registered with broadband 
decoupling. The (+) and (–) designations represent positive and negative intensities of 
signals in 13C DEPT-135 experiments. IR spectra were recorded on a ThermoFisher 
Nicolet™ iS™ 5 FT-IR Spectrometer. HRMS was carried out on an LCT Premier 
(Micromass Technologies) instrument employing ESI TOF detection techniques. 
Glassware used in moisture-free syntheses was flame-dried under vacuum prior to use. 
Column chromatography was carried out on silica gel (Sorbent Technologies, 40-63 μm). 
Pre-coated silica gel plates (Sorbent Technologies Silica XG 200 μm) were used for TLC 
analysis. Anhydrous DCM, THF, 1,4-dioxane, DME, MTBE, acetonitrile, and toluene 
were each prepared by refluxing commercially-available solvent over CaH2 followed by 
distillation under a stream of dry nitrogen at ambient pressure and stored over 4Å molecular 
sieves under dry nitrogen. Anhydrous DMSO and DMF were prepared by stirring at 100 
°C and 80 °C, respectively, over CaH2 followed by distillation under reduced pressure 
stored over 4Å molecular sieves under dry nitrogen. All reagents, unless otherwise 
specified were used in their commercially-available forms and purities. All manipulations 
of KOH and/or 18-crown-6 were conducted under inert atmosphere (<8 ppm residual 
oxygen and moisture) using a combination of glovebox and standard Schlenk techniques. 
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2.9.2 Synthesis of Diamines 
N-Benzyl-3-((tert-butoxycarbonyl)amino)propan-1-
aminium chloride (162a): A 15 mL autoclave vessel was 
charged with tert-butyl (3-(benzylamino)propyl)carbamate 
(400 mg, 2.30 mmol, 1 equiv.), benzaldehyde (279 μL, 2.75 mmol, 1.2 equiv.), 10 wt% 
palladium on carbon (29.3 mg, 7.3 wt%), methanol (3.5 mL), and chloroform (230 μL, 2.85 
mmol, 1.24 equiv.). The mixture was stirred at 750 RPM under hydrogen gas (1.4 atm) for 
10 hours. The catalyst was removed by vacuum filtration through Celite® 545 non-acid-
washed filter aid washing with methanol. Volatiles were removed under reduced pressure. 
The resultant solid was triturated with diethyl ether and collected via vacuum filtration to 
afford the title compound as a white powder (565 mg, 1.88 mmol, 82%); mp 148.2 – 150.1 
°C; 1H NMR (500 MHz, DMSO-d6) δ 9.12 (s, 2H), 7.57 – 7.51 (m, 2H), 7.46 – 7.38 (m, 
3H), 6.95 (t, J = 6.0 Hz, 1H), 4.12 (s, 2H), 2.98 (q, J = 6.5 Hz, 2H), 2.86 (t, J = 7.9 Hz, 
2H), 1.76 (p, J = 6.9 Hz, 2H), 1.37 (s, 9H); 13C NMR (126 MHz, DMSO-d6) δ 155.7, 132.0, 
130.0 (+), 128.9 (+), 128.6 (+), 77.8, 49.9 (–), 44.4 (–), 37.0 (–), 28.2 (–), 26.2 (–); FT IR 
(KBr, cm-1): 3368, 3338, 2977, 2941, 2766, 1687, 1531, 1457, 1368, 1289, 1175, 753, 698; 
HRMS (TOF ES): found 265.1910, calculated for C15H25N2O2 (M+) 265.1916 (2.3 ppm).  
 
3-((tert-Butoxycarbonyl)amino)-N-(4-
fluorobenzyl)propan-1-aminium chloride (162b): A 15 
mL autoclave vessel was charged with tert-butyl (3-
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(148 μL, 1.38 mmol, 1.2 equiv.), 10 wt% palladium on carbon (14.7 mg, 7.3 wt%), 
methanol (1.5 mL), and chloroform (114 μL, 1.42 mmol, 1.24 equiv.). The mixture was 
stirred at 750 RPM under hydrogen gas (1.4 atm) for 10 hours. The catalyst was removed 
by vacuum filtration through Celite® 545 non-acid-washed filter aid washing with 
methanol. Volatiles were removed under reduced pressure. The resultant solid was 
triturated with hot ethyl acetate and collected via vacuum filtration. Diamine 
dihydrochloride side product was selectively crystallized out in ethanol. The mother liquor 
was concentrated to afford the title compound as a pale yellow powder (311 mg, 0.98 
mmol, 85%); mp 187.4 °C (decomposed); 1H NMR (400 MHz, DMSO-d6) δ ppm 9.02 (br 
s, 2H), 7.58 (dd, J = 8.2, 5.5 Hz, 2H), 7.28 (t, J = 8.9 Hz, 2H), 6.96 (t, J = 5.9 Hz, 1H), 4.12 
(s, 2H), 2.98 (q, J = 6.4 Hz, 2H), 2.85 (s, 2H), 1.74 (p, J = 7.8 Hz, 2H), 1.37 (s, 9H). 13C 
NMR (126 MHz, DMSO-d6) δ ppm 162.37 (d, JCF = 245.6 Hz, 1C), 155.71, 132.45 (d, JCF 
J = 8.4 Hz, 2C, (+)), 128.30 (d, JCF = 2.6 Hz, 1C), 115.48 (d, JCF = 21.4 Hz, 2C, (+)), 77.74, 
49.08 (–), 44.27 (–), 36.99 (–), 28.20 (+), 26.26 (–); 19F NMR (471 MHz, DMSO-d6) δ ppm 
-112.83 – -112.91 (m); FT IR (KBr, cm-1): 3362, 2980, 2945, 2777, 2699, 2567, 2412, 
1680, 1516, 1443, 1368, 1287, 1225, 1170, 990, 833; HRMS (TOF ES): found 283.1831, 
calculated for C15H24FN2O2 (M+) 283.1822 (3.2 ppm). 
2.9.3 Synthesis of Cyclopropene Carboxamides 
 tert-Butyl (3-(N-benzyl-1-phenylcycloprop-2-ene-1-
carboxamido)propyl)carbamate (160): A flame-dried round bottom 
flask was charged with 1-phenylcycloprop-2-ene-1-carboxylic acid 
(760 mg, 4.74 mmol, 1.00 equiv.), anhydrous dichloromethane (21.3 mL), and DMF (5 
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drops) under nitrogen atmosphere. Oxalyl chloride (623 μL, 903 mg, 7.12 mmol, 1.5 
equiv.) was then added dropwise and the mixture was stirred at room temperature for 2h. 
Volatiles were removed under reduced pressure to provide the crude acyl chloride. To a 
flame-dried flask containing tert-butyl (3-(benzylamino)propyl)carbamate hydrochloride 
(162a) (1.65 g, 5.48 mmol, 1.16 equiv.), triethylamine (1.984 mL, 1.44 g, 14.23 mmol, 3 
equiv.), and anhydrous dichloromethane (9.2 mL) was added dropwise a solution of the 
crude acyl chloride in anhydrous dichloromethane (6.1 mL). The reaction mixture was 
stirred for 16 hours at RT. The mixture was diluted with dichloromethane (40 mL) and 
washed with 1N HCl (3 x 30 mL). The combined aqueous washes were back-extracted 
with dichloromethane (1 x 30 mL). The combined organic layers were then washed with 
brine (1 x 20 mL), dried with MgSO4, filtered, and concentrated under reduced pressure. 
The product was purified by column chromatography on silica gel eluting with 
DCM:EtOAc (7:1) to afford the title compound as a pale yellow oil (1.83 g, 4.50 mmol, 
95%); Rf  0.36 (DCM:EtOAc, 7:1); NMR spectra indicate the presence of two rotamers 
(ratio of 2.6:1): 1H NMR (500 MHz, CDCl3) δ ppm [7.35 (s) & 7.33-7.12 (m) & 7.13 (d, J 
= 7.1 Hz) & 7.09 (s) & 6.94 (d, J = 6.9 Hz) , Σ12H], [5.45 (t, J = 6.3 Hz) & 4.61 (s) & 4.49 
(s) & 4.27 (m), Σ3H], [3.37 (t, J = 6.7 Hz) & 3.23 (m), Σ2H], [3.13 (q, J = 6.3 Hz) & 2.79 
(q, J = 6.5 Hz), Σ2H], [1.66 (p, J = 6.5 Hz) & 1.41 (m), Σ11H]; 13C NMR (126 MHz CDCl3) 
δ ppm 175.1, 174.4, 156.2, 155.9, 143.3, 143.0, 137.6, 137.0, 128.9 (+), 128.8 (+), 128.7 
(+), 128.6 (+), 128.3 (+), 127.7 (+), 127.5 (+), 126.9 (+), 126.8 (+), 126.7 (+), 126.4 (+), 
126.0 (+), 110.4 (+), 109.9 (+), 79.4, 79.1, 51.3 (–), 47.6 (–), 44.6 (–), 42.1 (–), 38.0 (–), 
37.7 (–), 32.3, 32.1, 28.6 (+), 28.5 (+), 28.5 (–), 27.6 (–); FT IR (NaCl, cm-1): 3334, 3085, 
3061, 3028, 2976, 2931, 1708, 1623, 1514, 1495, 1452, 1425, 1365, 1273, 1250, 1171, 
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997, 737, 700, 654, 605; HRMS (TOF ES): found 429.2149, calculated for C25H30N2O3 
(M+Na) 429.2154 (1.2 ppm). 
 
3-(N-Benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propan-
1-aminium trifluoroacetate (161): tert-Butyl (3-(N-benzyl-1-
phenylcycloprop-2-ene-1-carboxamido)propyl)carbamate (156) 
(1.80 g, 4.43 mmol, 1 equiv.) was dissolved in dichloromethane (9.7 
mL). The solution was cooled to 0 °C and trifluoroacetic acid (9.7 mL) was added. The 
reaction mixture was then stirred at RT for 4 hours. Volatiles were removed under reduced 
pressure to afford the crude trifluoroacetate salt as a light brown oil (1.71 g, 4.08 mmol, 
92%). The material was used without further purification. 
 
3-(N-Benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propan-1-
aminium chloride (163): Gaseous hydrogen chloride was bubbled 
through a solution of (3-(N-benzyl-1-phenylcycloprop-2-ene-1-
carboxamido)propyl)carbamate (156) (589 mg, 1.45 mmol) in dichloromethane (25 mL) 
while stirring at rt. The reaction was allowed to proceed until TLC analysis indicated 
consumption of the protected amine (45 min). Volatiles were removed under reduced 
pressure. The resultant solid was triturated with diethyl ether and collected via vacuum 
filtration to afford the title compound as a white crystalline solid (390 mg, 1.14 mmol, 
79%); mp 89.1 °C (decomposed); NMR spectra indicate the presence of two rotamers (ratio 
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7.17 (m) & 7.12 – 7.05 (m) & 7.01 – 6.98 (m), Σ10H], [4.54 (s) & 4.52 (s), Σ2H], [3.26 (t, 
J = 7.9 Hz) & 3.21 (t, J = 7.2 Hz), Σ2H], [2.71 (q, J = 6.6 Hz) & 2.54 (q, J = 6.4 Hz), Σ2H], 
[1.78 (p, J = 7.4 Hz) & 1.72 – 1.64 (m), Σ2H]; FT IR (NaCl, cm-1): 3122, 3084, 2817, 2788, 
2712, 1590, 1531, 1441, 1430, 1367, 1242, 738, 709, 696, 662, 537; HRMS (TOF ES): 




Typical Procedure: An oven-dried 5 mL V-vial equipped with a 
magnetic spin vane was charged with 3-(N-benzyl-1-
phenylcycloprop-2-ene-1-carboxamido)propan-1-aminium 
chloride (163) (94 mg, 0.274 mmol, 1 equiv.), dichloromethane (1.5 mL), and triethylamine 
(115 μL, 83 mg, 0.822 mmol, 3 equiv.). The solution was cooled to 0 °C and 3,4-
dimethoxybenzenesulfonyl chloride (68.0 mg, 0.287 mmol, 1.05 equiv.) was added in a 
single portion. The reaction mixture was stirred at 0 °C for 2 hours. The reaction mixture 
was then stirred for an additional 16 hours at RT. The reaction mixture was diluted with 
dichloromethane (20 mL) and washed successively with 1M HCl (2 x 6 mL), 5% NaHCO3 
(2 x 6 mL), water (2 x 6 mL), and brine (1 x 8 mL). The organic layer was dried over 
MgSO4, filtered, and concentrated under reduced pressure. The product was purified by 
column chromatography on silica gel eluting with DCM:EtOAc (3:1) to afford the title 
compound as a thick, colorless oil (83 mg, 0.164 mmol, 60%); Rf = 0.26 (DCM:EtOAc, 
3:1) NMR spectra indicate the presence of two rotamers (ratio of 8:1): 1H NMR (500 MHz, 
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CDCl3) δ ppm [7.52 (dd, J = 8.4, 2.1 Hz) & 7.39 (d, J = 2.1 Hz) & 7.38 – 7.17 (m) & 7.09 
(s) & 6.97 (dd, J = 6.9, 2.8 Hz) & 6.93 – 6.88 (m), Σ15H], [6.08 (t, J = 5.5 Hz) & 4.59 (s) 
& 4.44 (s), 3.94 (s) & 3.93 (s) & 3.90 (s) & 3.60 (t, J = 5.9 Hz), Σ9H], [3.37 (t, J = 6.2 Hz) 
& 3.33 – 3.23 (m), Σ2H], [2.92 (q, J = 5.8 Hz) & 2.55 (q, J = 6.3 Hz), Σ2H], [1.62 (p, J = 
6.2 Hz) & 1.37 – 1.32 (m), Σ2H]; 13C NMR (126 MHz CDCl3) δ ppm 175.6, 152.4, 149.2, 
142.7, 136.4, 132.3, 129.0 (+), 128.8 (+), 128.7 (+), 128.2 (+), 127.9 (+), 126.9 (+), 126.9 
(+), 126.7 (+), 126.0 (+), 121.1 (+), 110.6 (+), 110.1 (+), 109.9 (+), 100.1, 56.4 (+), 56.3 
(+), 51.2 (–), 47.7 (–), 44.4 (–), 41.4 (–), 40.1 (–), 32.0, 29.9 (+), 27.3 (+). FT IR (NaCl, 
cm-1): 3269, 3148, 3103, 3061, 2934, 2856, 1613, 1509, 1443, 1325, 1262, 1237, 1182, 
1153, 1095, 1021, 765, 701, 578; HRMS (TOF ES): found 529.1759, calculated for 
C28H30N2O5S (M+Na) 529.1773 (2.6 ppm). 
 
 N-Benzyl-N-(3-(methylsulfonamido)propyl)-1-phenylcycloprop-2-
ene-1-carboxamide (129b): The compound was prepared according to 
the typical procedure employing 3-(N-benzyl-1-phenylcycloprop-2-
ene-1-carboxamido)propan-1-aminium chloride (163) (167 mg, 0.487 
mmol, 1 equiv.), triethylamine (204 μL, 148 mg, 1.46 mmol, 3 equiv.), and 
methanesulfonyl chloride (40 μL, 57 mg, 0.511 mmol, 1.05 equiv.) to yield the title 
compound as a thick, colorless oil (110 mg, 0.286 mmol, 59%); Rf = 0.29 (DCM:EtOAc, 
2:3); NMR spectra indicate the presence of two rotamers (ratio of 6.9:1): 1H NMR (500 
MHz, CDCl3) δ [7.42 (s) & 7.39 – 7.22 (m), Σ8H], [7.17 – 7.12 (m) & 6.99 – 6.94 (m), 
Σ3H], [5.85 (s) & 4.65 (s) & 4.55 (s), Σ3H], [3.54 (t, J = 6.1 Hz) & 3.47 (t, J = 6.2 Hz) & 
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3.38 – 3.32 (m) & 3.15 (t, J = 6.1 Hz), Σ4H], [3.07 – 3.01 (m) & 2.97 (s) & 2.80 (s) & 2.77 
– 2.71 (m), Σ3H], [1.73 (p, J = 6.1 Hz) & 1.46 (p, J = 6.8 Hz), Σ2H]; 13C NMR (126 MHz, 
CDCl3) δ 175.6, 174.4, 143.2, 142.7, 137.4, 136.3, 129.2 (+), 128.9 (+), 128.8 (+), 128.7 
(+), 128.6 (+), 128.1 (+), 127.8 (+), 126.9 (+), 126.8 (+), 126.6 (+), 126.3 (+), 125.9 (+), 
110.3 (+), 110.0 (+), 51.4 (–), 47.6 (–), 44.3 (–), 41.6 (–), 40.5 (–), 40.4 (+), 40.2 (–), 40.0 
(+), 32.2, 31.9, 28.4 (–), 28.0 (–); FT IR (NaCl, cm-1): 3259, 3062, 3030, 2932, 1721, 1623, 
1453, 1319, 1150, 1079, 975, 735, 702, 521; HRMS (TOF ES): found 407.1414, calculated 
for C21H24N2O3S (M+Na) 407.1405 (2.2 ppm). 
 
N-benzyl-N-(3-((2,5-dimethylphenyl)sulfonamido)propyl)-1-
phenylcycloprop-2-ene-1-carboxamide (129c): The compound was 
prepared according to the typical procedure employing 3-(N-benzyl-1-
phenylcycloprop-2-ene-1-carboxamido)propan-1-aminium chloride 
(163)  (115 mg, 0.274 mmol, 1 equiv.), triethylamine (114 μL, 83 mg, 
0.821 mmol, 3 equiv.), and 2,5-dimethylbenzenesulfonyl chloride (59 mg, 0.287 mmol, 
1.05 equiv.) to yield the title compound as a thick, colorless oil (73.9 mg, 0.156 mmol, 
57%); Rf = 0.35 (6:1, DCM:EtOAc); NMR spectra indicate the presence of two rotamers 
(ratio of 5.9:1): 1H NMR (500 MHz, CDCl3) δ [7.79 (d, J = 1.9 Hz) & 7.67 (s), Σ1H], [7.36 
(s) & 7.32 – 7.15 (m) & 7.13 (s) & 7.07 – 7.03 (m) & 6.93 – 6.89 (m), Σ14H], [6.09 (t, J = 
6.8 Hz) & 4.58 (s) & 4.44 (s) & 3.77 (t, J = 6.3 Hz), Σ3H], [3.38 (t, J = 6.2 Hz) & 3.30 – 
3.23 (m), Σ2H], [2.94 (q, J = 6.3 Hz) & 2.67 (s) & 2.51 (q, J = 6.5 Hz) & 2.47 (s) & 2.36 
(s), Σ8H], [1.57 (p, J = 6.1 Hz) & 1.33 (p, J = 6.7 Hz), Σ2H]; 13C NMR (126 MHz, CDCl3) 
       73 
 
δ 175.6, 174.5, 142.8, 138.4, 136.5, 136.3, 136.0, 135.5, 134.2, 133.7 (+), 133.2 (+), 132.6 
(2C, (+)), 130.1 (+), 129.8 (+), 129.6, 129.0 (+), 128.8 (2C, (+)), 128.7 (+), 128.2 (+), 127.9 
(+), 127.5 (+), 127.0 (+), 126.9 (+), 126.8 (+), 126.7 (+), 126.1 (+), 110.4 (+), 110.2 (+), 
51.2 (–), 47.6 (–), 44.4 (–), 41.4 (–), 40.3 (–), 39.9 (–), 32.4, 32.1, 28.0 (–), 27.6 (–), 21.0 
(+), 20.0 (+), 19.9 (+); FT IR (NaCl, cm-1): 3142, 3100, 3053, 3028, 2927, 2869, 1614, 
1451, 1427, 1207, 1151, 1095, 816, 738, 701, 682, 655, 594; HRMS (TOF ES): found 
497.1872, calculated for C28H30N2O3S (M+Na) 497.1875 (0.6 ppm). 
 
N-benzyl-N-(3-((4-methylphenyl)sulfonamido)propyl)-1-
phenylcycloprop-2-ene-1-carboxamide (129d): The compound was 
prepared according to the typical procedure employing 3-(N-benzyl-1-
phenylcycloprop-2-ene-1-carboxamido)propan-1-aminium chloride 
(163) (163 mg, 0.475 mmol, 1 equiv.), triethylamine (199 μL, 144 mg, 
1.43 mmol, 3 equiv.), and 4-methylbenzenesulfonyl chloride (95 mg, 0.499 mmol, 1.05 
equiv.) to yield the title compound as a thick, colorless oil (193 mg, 0.419 mmol, 88%). Rf 
= 0.32 (DCM:EtOAc, 6:1); NMR spectra indicate the presence of two rotamers (ratio of 
5.6:1): 1H NMR (500 MHz, CDCl3) δ ppm [7.79 (d, J = 8.2 Hz) & 7.61 (d, J = 8.0 Hz), 
Σ2H], [4.78 (s) & 7.32–7.16 (m) & 7.11 (s) & 7.01-6.95 (m) & 6.90 (d, J = 6.9 Hz) & 6.06 
(t, J = 6.6 Hz), Σ14H], [6.06 (t, J = 6.6 Hz) & 4.57 (s) & 4.43 (s) & 3.74 (t, J = 6.2 Hz), 
Σ3H], [3.36 (t, J = 6.2 Hz) & 3.26 (m), Σ2H], [2.91 (q, J = 6.3 Hz) & 2.54 (q, J = 6.2 Hz), 
Σ2H], [2.42 (s), 2.40 (s), [1.60 (p, J = 6.1 Hz) & 1.34 (p, J = 6.7 Hz), Σ2H]; 13C NMR (126 









       74 
 
(+), 128.7 (+), 128.2 (+), 127.9 (+), 127.5 (+), 127.3 (+), 127.1 (+), 127.0 (+), 126.8 (+), 
126.7 (+), 126.6 (+), 126.0 (+), 110.4 (+), 110.2 (+), 51.2 (–), 47.6 (–), 44.4 (–), 41.4 (–), 
40.5 (–), 40.1 (–), 32.0 (–), 28.0 (–), 27.3 (–), 21.6 (+); FT IR (KBr, cm-1): 3147, 3103, 
3061, 3028, 2925, 2869, 1612, 1445, 1426, 1207, 1152, 1093, 815, 738, 700, 658, 551; 




phenylcycloprop-2-ene-1-carboxamide (129e): The compound 
was prepared according to the typical procedure employing 3-(N-
benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propan-1-
aminium chloride (163) (115 mg, 0.335 mmol, 1 equiv.), 
triethylamine (140 μL, 102 mg, 1.00 mmol, 3 equiv.), and naphthalene-2-sulfonyl chloride 
(84 mg, 0.369 mmol, 1.05 equiv.) to yield the title compound as a thick, colorless oil (112 
mg, 226 mmol, 67%). Rf = 0.33 (DCM:EtOAc, 6:1); NMR spectra indicate the presence of 
two rotamers (ratio of 5.6:1): 1H NMR (500 MHz, CDCl3) δ [8.46 (s) & 8.32 (s), Σ2H], 
[7.97 – 7.86 (m) & 7.71 – 7.54 (m), Σ6H], [7.34 – 7.21 (m) & 7.19 – 6.99 (m) & 6.95 – 
6.92 (m) & 6.87 (dd, J = 7.4, 2.1 Hz), Σ12H], [6.30 (t, J = 6.7 Hz) 4.56 (s) & 4.40 (s) & 
3.83 (t, J = 6.5 Hz), Σ3H], [3.37 (t, J = 6.2 Hz) & 3.28 – 3.22 (m), Σ2H], [2.95 (q, J = 6.0 
Hz) & 2.57 (q, J = 6.4 Hz), Σ2H], [1.59 (p, J = 6.1 Hz) & 1.34 (p, J = 6.7 Hz), Σ2H]; 13C 
NMR (126 MHz, CDCl3) δ 175.7, 142.6, 137.5, 136.4, 134.9, 132.4, 129.7 (+), 129.5 (+), 
129.4 (+), 129.3 (+), 129.2 (+), 129.1 (+), 129.0 (+), 128.9 (+), 128.7 (2C, (+)) 128.6 (+), 
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128.5 (+), 128.3 (+), 128.3 (+), 128.2 (+), 128.0 (+), 127.9 (+), 127.5 (+), 127.1 (+), 127.0 
(+), 126.8 (+), 126.7 (+), 126.4 (+), 126.0 (+), 122.8 (+), 122.3 (+), 110.4 (+), 110.2 (+), 
51.2 (–), 47.6 (–), 44.4 (–), 41.4 (–), 40.6 (–), 40.1 (–), 32.4, 32.0, 28.0 (–), 27.3 (–); FT IR 
(NaCl, cm-1): 3276, 3149, 3105, 3058, 3029, 2935, 2872, 1611, 1494, 1425, 1328, 1267, 
1157, 1131, 1076, 818, 735, 700, 616, 550, 478; HRMS (TOF ES): found 519.1734, 




phenylcycloprop-2-ene-1-carboxamide (129f): The compound was 
prepared according to the typical procedure employing 3-(N-benzyl-
1-phenylcycloprop-2-ene-1-carboxamido)propan-1-aminium 
chloride (122 mg, 0.356 mmol, 1 equiv.), triethylamine (149 μL, 108 
mg, 1.07 mmol, 3 equiv.), and 4-bromobenzenesulfonyl chloride (163) (95 mg, 0.374 
mmol, 1.05 equiv.) to yield the title compound as a colorless oil (102 mg, 0.194 mmol, 
55%); Rf = 0.28 (hexanes:EtOAc:MeOH, 7:2:1); NMR spectra indicate the presence of two 
rotamers (ratio of 7.9:1): 1H NMR (500 MHz, CDCl3) δ ppm [7.77 – 7.73 (m) & 7.63 – 
7.55 (m),  Σ4H], [7.36 (s) & 7.32 – 7.14 (m) & 7.11 (s) & 7.01 – 6.96 (m) & 6.91 – 6.87 
(m), Σ12H], [6.37 (t, J = 6.6 Hz) & 4.57 (s) & 4.45 (s) & 4.19 (t, J = 6.4 Hz), Σ3H], [3.36 
(t, J = 6.2 Hz) & 3.30 – 3.23 (m), Σ2H], [2.90 (q, J = 6.1 Hz) & 2.53 (q, J = 6.3 Hz), Σ2H], 
[1.60 (p, J = 6.1 Hz & 1.37 (p, J = 6.6 Hz), Σ2H]; 13C NMR (126 MHz CDCl3) δ ppm 
175.9, 174.9, 143.1, 142.5, 139.6, 138.8, 137.2, 136.1, 132.5 (+), 132.4 (+), 129.0 (+), 
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128.9 (+), 128.8 (+), 128.8 (+), 128.7 (+), 128.6 (+), 128.2 (+), 128.0 (+), 127.6 (+), 127.0 
(+), 126.8 (+), 126.6 (+), 125.9 (+), 110.3 (+), 110.1 (+), 51.4 (–), 47.7 (–), 44.4 (–), 41.6 
(–), 40.5 (–), 40.1 (–), 32.2, 31.9, 27.9 (–), 27.3 (–); FT IR (NaCl, cm-1): 3262, 3149, 3105, 
3062, 3029, 2933, 2872, 1612, 1576, 1494, 1426, 1357, 1163, 1010, 823, 736, 700, 654, 
605, 562; HRMS (TOF ES): found 547.0645, calculated for C26H25BrN2O3S (M+Na) 
547.0667 (4.0 ppm). 
 
N-benzyl-N-(3-((4-nitrophenyl)sulfonamido)propyl)-1-
phenylcycloprop-2-ene-1-carboxamide (129g): The compound 
was prepared according to the typical procedure employing 3-(N-
benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propan-1-
aminium chloride (163) (94 mg, 0.274 mmol, 1 equiv.), 
triethylamine (115 μL, 83 mg, 0.822 mmol, 3 equiv.), and 4-nitrobenzenesulfonyl chloride 
(64 mg, 0.288 mmol, 1.05 equiv.) to yield the title compound as a thick, colorless oil (112 
mg, 0.228 mmol, 83%); Rf = 0.29 (DCM:EtOAc, 6:1); NMR spectra indicate the presence 
of two rotamers (ratio of 14.5:1): 1H NMR (500 MHz, CDCl3) δ [8.29 (d, J = 8.9 Hz) & 
8.08 (d, J = 8.8 Hz) & 7.89 (d, J = 8.5 Hz), Σ4H], [7.38 (s) & 7.32 – 7.26 (m) & 7.25 – 
7.17 (m) & 7.12 (s) & 6.98 (dd, J = 7.5, 2.1 Hz) & 6.91 – 6.88 (m) & 6.82 (t, J = 6.5 Hz) 
& Σ15H], [4.59 (s) & 4.47 (s), Σ2H], [3.39 (t, J = 6.1 Hz) & 3.32 – 3.27 (m), Σ2H], [2.96 
(q, J = 6.1 Hz) & 2.64 – 2.54 (m), Σ2H], [1.61 (p, J = 6.1 Hz) & 1.44 – 1.37 (m), Σ2H]; 
13C NMR (126 MHz, CDCl3) δ 176.0, 150.0, 146.6, 142.5, 136.0, 129.1 (+), 128.8 (+), 
128.5 (+), 128.1 (+), 127.0 (+), 127.0 (+), 125.8 (+), 124.3 (+), 110.1 (+), 51.5 (–), 41.4 (–
       77 
 
), 40.2 (–), 31.9, 27.4 (–); FT IR (NaCl, cm-1): 3145, 3103, 3064, 3029, 2933, 2866, 1608, 
1529, 1445, 1426, 1207, 1152, 1093, 855, 737, 700, 610, 554; HRMS (TOF ES): found 




carboxamide (129h): The compound was prepared according to the 
typical procedure employing 3-(N-benzyl-1-phenylcycloprop-2-ene-1-
carboxamido)propan-1-aminium chloride (163) (250 mg, 0.729 mmol, 
1 equiv.), triethylamine (305 μL, 221 mg, 2.19 mmol, 3 equiv.), and (1S)-(+)-10-
camphorsulfonyl chloride (201 mg, 0.802 mmol, 1.1 equiv.) to yield the title compound as 
a thick, pale yellow oil (215 mg, 0.413 mmol, 57%); Rf = 0.31 (DCM:EtOAc, 3:1); NMR 
spectra indicate the presence of two rotamers (ratio of 3:1): 1H NMR (500 MHz, CDCl3) δ 
[7.41 (d, J = 4.9 Hz, 1H), 7.36 – 7.23 (m), 7.20 (dd, J = 9.2, 5.0 Hz), 7.17 – 7.09 (m), 6.98 
– 6.94 (m), Σ12H], [5.82 (t, J = 6.5 Hz), 4.74 (t, J = 6.2 Hz), 4.69 – 4.57 (m), 4.52 (m), 
Σ3H], [δ  3.52 – 3.27 (m), 3.23 (d, J = 15.2 Hz), 3.18 (q, J = 6.4 Hz), 2.91 (d, J = 15.0 Hz), 
2.86 – 2.73 (m), 2.40 (p, J = 3.3, 2.9 Hz), 2.36 (t, J = 3.8 Hz), 2.22 – 2.12 (m), 2.11 (t, J = 
4.6 Hz), 2.04 (tq, J = 12.2, 4.2 Hz), 1.92 (d, J = 18.6 Hz), 1.84 (ddd, J = 14.3, 9.4, 4.8 Hz), 
1.76 (tt, J = 10.6, 5.2 Hz), 1.46 (dddd, J = 29.4, 13.0, 7.8, 3.7 Hz), Σ15H], [1.07 (s), 1.00 
(s), Σ3H], [0.89 (s), 0.88 (s,), Σ3H]; 13C NMR (126 MHz, CDCl3) δ 217.3, 216.5, 175.3, 
174.6, 143.3, 143.0, 137.6, 136.8, 129.0 (+), 128.8 (+), 128.7 (+), 128.7 (+), 128.3 (+), 
127.8 (+), 127.5 (+), 127.0 (+), 126.8 (+), 126.7 (+), 126.6 (+), 126.1 (+), 110.8 (+), 110.2 
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(+), 110.0 (+), 109.9 (+), 59.3, 59.0, 51.5 (–), 49.3 (–), 49.2 (–), 49.0, 48.6, 47.7 (–), 44.6 
(–), 43.1 (–), 43.0 (–), 42.9 (+), 42.0 (–), 41.2 (–), 40.9 (–), 32.3, 32.1, 29.8 (–), 28.6 (–), 
28.2 (–), 27.2 (–), 26.7 (–), 25.9 (–), 20.0 (+), 20.0 (+), 19.9 (+), 19.6 (+). FT IR (NaCl, 
cm-1): 3281, 3205, 3148, 3103, 3060, 3028, 2958, 2887, 1743, 1645, 1618, 1446, 1424, 
1329, 1146, 1067, 736, 700, 607, 567; HRMS (TOF ES): found 543.2292, calculated for 
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Chapter 3. Strain-Release Activated Intramolecular Addition of Nitrogen 
Nucleophiles to 3,3-Disubtituted Cyclopropenes to Form 3,4-Cyclopropane-Fused 
1,5-Diazocin-2-ones 
3.1 Introduction 
The previous chapter details the development of pronucleophilic synthetic 
precursors 129 for the base-assisted 8-exo-trig cyclization to form 3,4-cyclopropane-fused 
1,5-diazocin-2-ones 131 (Scheme 52).  
Scheme 52 
 
Annulated cyclopropane moieties can be found in marketed drugs such as broad 
spectrum antibiotic Trovafloxacin and the oral anti-diabetic Saxagliptin (Figure 8), as well 
as drug candidates like the anti-HCV BMS-791325. The cyclopropane moiety imparts 
rigidity to molecular scaffolds, allowing for the fixed spatial orientation of its 
substituents.84 The development of new synthetic methods toward cyclopropane-annulated 
       80 
 
target allows for the design of new drug candidates from unexplored chemical space which 





























Figure 8: Marketed drugs and drug candidates featuring annulated cyclopropanes. 
In our labs, annulated cyclopropanes which exhibit impressive biological activities 
have been synthesized. For example, cyclopropane-fused oxazepanone shown in Figure 9 
exhibited promising activity against Mycobacterium abscessus with apparent low general 
toxicity against cultured human cells.58  
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Figure 9: A cyclopropane-fused oxazepanone synthesized in our labs which possesses promising anti-
mycobacterial activity. 
 The bioactivity of this example, and those similar in structure, warrant the further 
exploration of annulated cyclopropanes as potential drug candidates. In this chapter, a 
protocol for the effective synthesis of a novel class of 1,5-diazocin-2-ones – featuring 3,4-
fusion to a cyclopropane moiety – is described.  
 
3.2 Origins of Difficulty in the Direct Cyclization of Medium-Sized Rings 
Although perhaps the most straightforward route to medium-sized (7- to 11-
membered) cycles, the direct cyclization of such systems is inherently difficult. This is due 
to both entropic and enthalpic factors present both in the transition states and in the final 
products of such transformations – i.e. reflective of ΔGǂ and ΔG, respectively. The seminal 
work by Mandolini14 in 1986 offers a thorough analysis of the kinetics and thermodynamics 
of simple cyclization systems of varying ring size, and in turn provides explanations of 
these phenomena. The lactonization of ω-bromoalkanoate anions (Scheme 53) provides a 
simple model for cyclizations affording cyclic carboxylic acid derivatives and is one for 
which a nearly complete set of experimental data is available.  













The rates of cyclization are highly dependent on the number of members in the 
forming cycle (Figure 10); with differing dominating factor(s) depending on whether 
small-, medium-, or large-sized rings are considered. A common theme, however, is the 
amount of ring strain associated with the transition states and the products of cyclization 
(Figure 11). The lactonizations of small (particularly 3-membered) systems exhibit low  
 
Figure 10: Experimental rate constants of the lactonization of ω-bromoalkanoate anions in 99:1 DMSO:H2O 

















The Rates of Lactonizations of ω-Bromoalkanoate Anions
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rates of intramolecular reaction when compared to the rapid 5-membered lactonization due 
to the high degree of both angle and torsional strain (a.k.a. Baeyer and Pitzer strain, 
respectively) in the transition states and in the products. Homologous reactions of large 
(12-members and larger) systems exhibit reaction rates very close to that of the cyclization 
of the 3-membered lactone. Their increased flexibility allows for conformational 
adjustments which minimize both angle strain and torsional strain. Because of this, these 
large cycles incur only a very small enthalpic penalty in both the transition state and in the 
product. However, despite the relatively high level of conformational freedom present in 
the product, the high entropic cost imposed in the transition state has been shown to be 
most primarily responsible for the low reaction rates. Figure 10 shows a sharp decline into 
 




























Strain Energy of Lactonization
Cycle Strain Energy
TS Strain Energy
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a kinetic valley appearing in the region of 7- to 11-membered cyclizations – the region 
corresponding to medium-sized rings. In this range, a third type of strain becomes 
important: transannular strain (a.k.a. Prelog strain). Transannular strain arises due to steric 
repulsion between substituents positioned across the ring system. The calculated lowest 
energy conformation of 8-membered oxocan-2-one is shown in Figure 12. Interactions of 
H-1 with H-3, and of H-2 with H-3, are prime examples of transannular strain. In both 
cases, the hydrogens are involved in destabilizing steric interactions across the ring which 
are not present to a significant degree in small- or large-sized cycles in their lowest energy 
conformations. Any relief of transannular strain by way of conformational adjustment 
results in increased torsional and/or angle strain. 
 
Figure 12: The transannular strain of oxocan-2-one. Several hydrogens on the right-most graphic are not 
shown for the purpose of clarity. Calculation: gas phase, ground state, geometry-optimized, (HF 6-
311++G(d,p)) (see Appendix A1).85 
The high degree to which some combination of angle, torsional, and transannular strain is 
present in both the transition state and the product is unique to medium-sized rings and 
imposes a strong enthalpic cost on their formation. Further, a sizeable entropic cost also 
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accompanies the formation of these cycles in the transition state; although the medium-
sized ring products themselves pay a significantly lower entropic penalty.14  
 
3.3 Initial Reaction and Optimization of Reaction Conditions 
 The energy of the cyclopropene double bond is effective in mitigating the enthalpic 
difficulties inherent to the formation of 8-membered heterocycles. Employing conditions 
previously optimized in the Rubin group72 for the intermolecular addition of sulfonamides 
to in situ generated conjugated cyclopropenes (Table 1, Entry 1), the 8-exo-trig cyclization 
of tosylsulfonamide 129d was attempted (Scheme 54). The reaction  
Scheme 54 
 
afforded a single major compound. The isolated product was analyzed by 1D and 2D NMR 
to confirm the structure (See Appendix 3). It was confirmed that primary sulfonamide 129d 
was successfully cyclized to afford 1,5-diazocin-2-one 164d in good yield (79%) in just 
over an hour at 70 °C. 
We believe this cyclization to take place in a metal-templated fashion (Figure 13) 
wherein a potassium cation – supplied by the base – coordinates to the carbonyl oxygen, 
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the cyclopropene π-bond, and the anionic nucleophile, arranging the members of the 
forming cycle into a cyclic array, thereby lowering the energy of the transition state and 
facilitating the reaction.  
 
Figure 13: Proposed potassium-templated transition State 
The successful synthesis of diazocine 164d prompted the optimization of reaction 
conditions (Table 1). The phase transfer catalyst (18-crown-6) was found to have no 
observable effect on the reaction under these conditions and therefore was deemed to be 
unnecessary. A reduction in reaction temperature from 70 °C to 50 °C resulted in longer 
reaction times and slightly higher yield (Table 1, Entry 3). The remainder of optimization 
reactions were allowed to run over the course of 14 hours (overnight) as a matter of 
convenience. The reaction performed well in ethereal solvents in general (Table 1, Entries 
3-6) while providing dissatisfactory yields in more polar aprotic solvents (Table 1, Entries 
7-9). The reaction yield suffers slightly in toluene (Table 1, Entry 10). DMSO and DMF 
provided particularly low yields after 14 hours, despite full conversion being achieved. It 
is rationalized here that the ability of such solvents to solvate the potassium cation disrupts 
the formation of the necessary cyclic transition state (see Figure 13), while ethereal and  
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1 10 1.2 THF 70 7 25 79 
2 0 1.2 THF 70 7 25 79 
3 0 6.5 THF 50 7 25 82 
4 0 14 1,4-dioxane 50 7 25 83 
5 0 14 DME 50 7 25 80 
6 0 14 MTBE 50 7 25 77 
7 0 14 DMSO 50 7 25 32 
8 0 14 DMF 50 7 25 54 
9 0 14 MeCN 50 7 25 67 
10 0 14 toluene 50 7 25 70 
11 0 14 THF 50 5 25 85 
12 0 14 THF 50 4 25 89 
13 0 14 THF 50 2 25 94 
14 0 14 THF 50 1 25 ICb 
15 0 14 THF 50 2 12.5 95 
16 0 14 THF 50 2 37.5 95 
17 0 14 THF 50 2 50 95 
aNMR yields employing dibromomethane as the internal calibrant. bReaction proceeded with incomplete 
conversion of starting material. 
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hydrocarbon solvents are much less able to solvate the cation and therefore permits its 
formation to a much higher degree. As the base loading was systematically varied, it was 
found that the addition of fewer equivalents of potassium hydroxide, to a point, was 
accompanied by increased yields (Table 1, Entries 11-14). It is possible that partial 
hydrolysis of the sulfonamido group competes with the cyclization. Employing only a 
single equivalent of base resulted in incomplete conversion of the starting material (Table 
1, Entry 14). The increase or decrease of the reaction concentration was proved to have no 




3.4 Synthesis of 3,4-Cyclopropane-Fused 1,5-Diazocin-2-ones via 8-exo-trig 
Cyclization 
With optimized reaction conditions in hand, the synthesis of several examples of 
diazocinones 164 was carried out (Figure 14). 3,4-Dimethoxyphenyl cyclic sulfonamide 
164a – possessing the most electron-donating sulfonamido group of the series – provided 
the highest isolated yield of 93%. Similarly high yields were obtained in the cases of 164b, 
164c, 164d, and 164e. Compound 164f – bearing the slightly electron withdrawing p-
bromophenyl sulfonamido group – saw a significant decline in yield. In the case of p-
nitrophenyl cyclic sulfonamide 164g, the reaction required 20 hours (in contrast to the 
normal 14 hours) to proceed to completion. This reaction provided the lowest yield of the 
series. Thus, cyclization precursors 129 bearing electron-donating or groups that are 
relatively neutral in this regard, produce higher yields than those bearing electron-  
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withdrawing groups. Example 164h was derived from enantiopure (+)-camphorsulfonyl 
chloride, but provided no significant diastereoselectivity (~1:1 by NMR) and produced a 
preparatively inseparable mixture of diastereomers. The mixture was inseparable via 
analytical HPLC as well. The lack of selectivity is reasonable as the stereogenic centers of 
the camphorsulfonyl group are quite remote to the site of nucleophilic attack and therefore 
cannot induce a large difference in the energies of the two possible diastereomeric 
transition states.  
 
3.5 Conclusion 
1,5-Diazocin-2-ones 164 represent the first known class of such azalactams featuring 
fusion to a cyclopropane ring. With the unique structural features imparted by the fused 
cyclopropane moiety comes the possibility of unique biological activity and/or enhanced 
bioactivity of analogous diazocines which lack this cyclopropane fusion. The sulfonyl 
functional groups of the cycles were varied, showing that strongly electron withdrawing 
groups negatively affect the yields of these cycles. Further diversification of these 










diazabicyclo[6.1.0]nonan-7-one (164a): Typical Procedure: A 5 mL 
oven-dried v-vial equipped with a magnetic spin vane was charged with 
N-benzyl-N-(3-((4-methylphenyl)sulfonamido)propyl)-1-
phenylcycloprop-2-ene-1-carboxamide (129a) (19.5 mg, 0.038 mmol, 1 
equiv.), freshly-ground potassium hydroxide (4.3 mg, 0.077 mmol, 2 equiv.), and dry THF 
(800 μL). The reaction mixture was stirred overnight (14 h) at 50 °C. The reaction mixture 
was allowed to cool RT and passed through a short plug of silica eluting with EtOAc. 
Solvent was removed from the resulting solution via rotary evaporation. The product was 
purified by column chromatography on silica gel eluting with hexanes:EtOAc (2:3) to 
afford the title compound as a white solid (18.1 mg, 0.036 mmol, 93%); Rf = 0.35 
(hexanes:EtOAc, 2:3); mp 194-198 °C; 1H NMR (500 MHz, CDCl3) δ ppm 7.47 (dd, J = 
8.4, 2.1 Hz, 1H), 7.34-7.17 (m, 9H), 7.12 (dd, 7.2, 1.7 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 
5.31 (d, J = 14.8 Hz, 1H), 4.16 (dt, J = 14.0, 3.6 Hz, 1H), 4.04 (d, J = 14.9 Hz, 1H), 3.97 
(s, 3H), 3.95 (s, 3H), 3.68 (dd, J = 15.7, 10.9 Hz, 1H), 3.05 (dd, J = 15.6, 6.3 Hz, 1H), 2.77-
2.65 (m, 3H), 1.95 (dtd, J = 15.8, 11.5, 4.6 Hz, 1H), 1.60-1.50 (m, 1H), 1.33 (p, J = 5.6 Hz, 
1H); 13C NMR (126 MHz CDCl3) δ ppm 169.3, 153.9, 149.3, 138.7, 137.5, 129.5, 129.0 
(+), 128.7 (+), 128.4 (+), 127.6 (+), 127.2 (+), 125.5 (+), 121.7 (+), 110.9 (+), 110.4 (+), 
56.5 (+), 56.4 (+), 53.5 (–), 49.3 (–), 46.6 (+), 46.0 (–), 28.3 (–), 23.9 (–); FT IR (NaCl, 
cm-1): 3060, 3027, 2965, 2934, 2848, 1641, 1587, 1509, 1441, 1346, 1263, 1140, 1020, 
733, 702, 573; HRMS (TOF ES): found 529.1778, calculated for C28H30N2O5S (M+Na) 
529.1773 (0.9 ppm). 




diazabicyclo[6.1.0]nonan-7-one (164b): The compound was prepared 
according to the typical procedure employing N-benzyl-N-(3-
(methylsulfonamido)propyl)-1-phenylcycloprop-2-ene-1-carboxamide 
(129b) (32.7 mg, 0.085 mmol, 1 equiv.) and freshly-ground potassium hydroxide (9.5 mg, 
0.170 mmol, 2 equiv.) to yield the title compound as a white crystalline solid (30.2 mg, 
0.079 mmol, 92%). Rf = 0.23 (hexane:EtOAc:MeOH, 6:3:1, 0.2% TFA); mp 131 °C 
(decomposed); 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.23 (m, 8H), 7.19 – 7.15 (m, 2H), 
5.28 (d, J = 15.4 Hz, 1H), 4.19 (dt, J = 14.2, 3.8 Hz, 1H), 4.11 (d, J = 14.7 Hz, 1H), 3.79 
(dd, J = 15.5, 11.0 Hz, 1H), 3.17 – 3.11 (m, 2H), 3.05 (ddd, J = 15.0, 12.4, 3.0 Hz, 1H), 
2.93 (s, 3H), 2.59 (dd, J = 7.1, 5.3 Hz, 1H), 2.00 – 1.87 (m, 1H), 1.67 – 1.57 (m, 1H), 1.49 
(t, J = 7.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 170.0, 138.2, 137.0, 129.2 (+), 128.9 
(+), 128.6 (+), 127.9 (+), 127.4 (+), 125.4 (+), 52.9 (–), 49.6 (–), 46.6 (+), 46.3 (–), 38.2 
(+), 36.6, 28.2 (–), 23.4 (–); FT IR (NaCl, cm-1): 3083, 3060, 2923, 2907, 2850, 1701, 1638, 
1446, 1350, 1167, 823, 745, 700, 614, 580, 542; HRMS (TOF ES): found 407.1388, 
calculated for C21H24N2O3S (M+Na) 407.1405 (4.2 ppm). 
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 (1S*,8S*)-6-Benzyl-2-((2,5-dimethylphenyl)sulfonyl)-8-phenyl-2,6-
diazabicyclo[6.1.0]nonan-7-one (164c): The compound was prepared 
according to the typical procedure employing N-benzyl-N-(3-((2,5-
dimethylphenyl)sulfonamido)propyl)-1-phenylcycloprop-2-ene-1-
carboxamide (129c) (28.3 mg, 0.060 mmol, 1 equiv.) and freshly-
ground potassium hydroxide (6.7 mg, 119 mmol, 2 equiv.) to yield the title compound as 
a white crystalline solid (24.7 mg, 0.052 mmol, 87%); Rf = 0.33 (hexanes:EtOAc:MeOH, 
7:2:1); mp 182-185 °C; 1H NMR (500 MHz, CDCl3) δ ppm 7.86 (d, J = 2.0 Hz, 1H), 7.35-
7.19 (m, 10H), 7.16 (dd, J = 7.4, 1.8 Hz, 2H), 5.43 (d, J = 14.7 Hz, 1H), 4.37 (dt, J = 14.6, 
3.8 Hz, 1H), 3.90 (d, J = 14.7 Hz, 1H), 3.74 (dd, J = 15.7, 11.0 Hz, 1H), 3.16 (dd, J = 8.0, 
5.4 Hz, 1H), 3.11 – 2.99 (m, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 1.98 – 1.83 (m, 2H), 1.68 – 
1.58 (m, 2H), 1.19 (dd, J = 8.0, 6.7 Hz, 1H); 13C NMR (126 MHz CDCl3) δ ppm 169.4, 
138.6, 137.3, 136.6, 136.2, 135.3, 134.4 (+), 133.0 (+), 131.1 (+), 129.0 (+), 128.8 (+), 
128.5 (+), 127.7 (+), 127.1 (+), 125.5 (+), 51.7 (–), 48.9 (–), 46.3 (+), 45.7 (–), 36.5, 28.0 
(–), 23.3 (–), 21.0 (+), 19.9 (+); FT IR (NaCl, cm-1): 3060, 3029, 2923, 1641, 1494, 1441, 
1323, 1156, 821, 735, 713, 701, 588; HRMS (TOF ES): found 497.1876, calculated for 
C28H30N2O3S (M+Na) 497.1875 (0.2 ppm). 
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(1S*,8S*)-6-Benzyl-8-phenyl-2-tosyl-2,6-diazabicyclo[6.1.0]nonan-7-
one (164d): The compound was prepared according to the typical 
procedure employing N-benzyl-N-(3-((2,5-
dimethylphenyl)sulfonamido)propyl)-1-phenylcycloprop-2-ene-1-
carboxamide (129d) (25.0 mg, 0.054 mmol, 1 equiv.) and freshly-ground 
potassium hydroxide freshly-ground potassium hydroxide (6.1 mg, 0.109 
mmol, 2 equiv.) to yield the title compound as a white solid (22.8 mg, 0.049 mmol, 91%); 
Rf = 0.36 (hexanes:EtOAc, 3:2); mp 172-174 °C; 1H NMR (500 MHz, CDCl3) δ ppm 7.74 
(d, J = 8.3 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.33-7.16 (m, 8H), 7.12 (dd, J = 7.1, 1.8 Hz, 
1H), 5.31 (d, J = 14.8 Hz, 1H), 4.16 (dt, J = 13.9, 3.4 Hz, 1H), 4.06 (d, J = 14.8 Hz, 1H), 
3.67 (dd, J = 15.6, 11.0 Hz, 1H), 3.06 (dd, J = 15.6, 6.3 Hz, 1H), 2.74-2.62 (m, 3H), 2.46 
(s, 2H), 1.97 (dtd, J = 15.7, 11.9, 4.6 Hz, 1H), 1.55 (ddt, J = 14.8, 5.6, 2.4 Hz, 1H), 1.36 
(dd, J = 7.1, 6.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 169.3, 144.1, 138.8, 137.6, 134.8, 
130.1 (+), 129.0 (+), 128.8 (+), 128.5 (+), 127.9 (+), 127.7 (+), 127.2 (+), 125.6 (+), 53.6 
(–), 49.4 (–), 46.8 (+), 46.1, 36.7, 28.4 (–), 23.9 (–), 21.8 (+); FT IR (NaCl, cm-1): 3061, 
3030, 2961, 2924, 2855, 1641, 1598, 1495, 1479, 1442, 1425, 1380, 1344, 1165, 1129, 
1090, 816, 734, 712, 699, 563, 551, 541; HRMS (TOF ES): found 483.1721, calculated for 
C27H28N2O3S (M+Na) 483.1718 (0.6 ppm). 
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 (1S*,8S*)-6-Benzyl-2-(naphthalen-1-ylsulfonyl)-8-phenyl-2,6-
diazabicyclo[6.1.0]nonan-7-one (164e): The compound was prepared 
according to the typical procedure employing N-benzyl-N-(3-
(naphthalene-2-sulfonamido)propyl)-1-phenylcycloprop-2-ene-1-
carboxamide (129e) (26.7 mg, 0.054 mmol, 1 equiv.) and freshly-ground 
potassium hydroxide (6.0 mg, 0.108 mmol, 2 equiv.) to yield the title 
compound as a white crystalline solid (23.9 mg, 0.048 mmol, 90%); Rf = 0.38 
(hexanes:EtOAc:MeOH, 7:2:1); mp 185-190 °C (decomposed); 1H NMR (500 MHz, 
CDCl3) δ 8.34 (d, J = 1.8 Hz, 1H), 7.92 (t, J = 7.8 Hz, 2H), 7.88 – 7.84 (m, 1H), 7.75 (dd, 
J = 8.7, 1.8 Hz, 1H), 7.57 (dddd, J = 19.9, 8.0, 6.9, 1.3 Hz, 2H), 7.24 – 7.05 (m, 8H), 7.01 
– 6.97 (m, 2H), 5.22 (d, J = 14.8 Hz, 1H), 4.16 (dt, J = 14.0, 3.8 Hz, 1H), 3.97 (d, J = 14.8 
Hz, 1H), 3.58 (dd, J = 15.7, 11.0 Hz, 1H), 2.96 (dd, J = 15.6, 6.3 Hz, 1H), 2.75 – 2.54 (m, 
3H), 1.99 – 1.78 (m, 1H), 1.51 – 1.44 (m, 1H), 1.31 (dd, J = 7.9, 6.6 Hz, 1H); 13C NMR 
(126 MHz, CDCl3) δ 169.2, 138.6, 137.5, 135.1, 134.8, 132.4, 129.6 (+), 129.5 (+), 129.2 
(+), 129.2 (+), 129.0 (+), 128.8 (+), 128.5 (+), 128.2 (+), 127.9 (+), 127.6 (+), 127.2 (+), 
125.5 (+), 122.9 (+), 53.7 (–), 49.3 (–), 46.7 (+), 46.0 (–), 36.8, 28.4 (–), 23.9 (–); FT IR 
(NaCl, cm-1): 3060, 3041, 2965, 2855, 1641, 1598, 1447, 1442, 1425, 1360, 1344, 1165, 
1090, 816, 734, 712, 699, 655, 563, 551, 541; HRMS (TOF ES): found 519.1748, 
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 (1S*,8S*)-6-Benzyl-2-((4-bromophenyl)sulfonyl)-8-phenyl-2,6-
diazabicyclo[6.1.0]nonan-7-one (164f): The compound was prepared 
according to the typical procedure employing N-benzyl-N-(3-((4-
bromophenyl)sulfonamido)propyl)-1-phenylcycloprop-2-ene-1-
carboxamide (129f) (27.9 mg, 0.053 mmol, 1 equiv.) and freshly-ground 
potassium hydroxide (6.0 mg, 0.11 mmol, 2 equiv.) to yield the title 
compound as a white crystalline solid (22.0 mg, 0.042 mmol, 79%); Rf = 0.25 
(hexanes:EtOAc:MeOH, 7:2:1); mp 151 °C (decomposed); 1H NMR (500 MHz, CDCl3) δ 
7.77 – 7.67 (m, 4H), 7.35 – 7.18 (m, 8H), 7.14 – 7.10 (m, 2H), 5.29 (d, J = 14.8 Hz, 1H), 
4.18 – 4.11 (m, 1H), 4.09 (d, J = 14.8 Hz, 1H), 3.69 (dd, J = 15.7, 11.0 Hz, 1H), 3.08 (dd, 
J = 15.6, 6.3 Hz, 1H), 2.78 – 2.71 (m, 1H), 2.71 – 2.65 (m, 2H), 2.03 – 1.93 (m, 1H), 1.61 
– 1.54 (m, 1H), 1.37 (dd, J = 6.9, 5.7 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 169.3, 138.3, 
137.3, 136.8, 132.7 (+), 129.3 (+), 129.1 (+), 128.8 (+), 128.5 (+), 128.4, 127.7 (+), 127.3 
(+), 125.5 (+), 53.6 (–), 49.4 (–), 46.5 (–), 46.0 (–), 36.8, 29.9, 28.3 (–), 23.7 (–); FT IR 
(NaCl, cm-1): 3087, 3061, 2920, 2850, 1703, 1640, 1445, 1349, 1167, 822, 745, 700, 609, 
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 (1S*,8S*)-6-Benzyl-2-((4-nitrophenyl)sulfonyl)-8-phenyl-2,6-
diazabicyclo[6.1.0]nonan-7-one (164g): The compound was prepared 
according to the typical procedure employing N-benzyl-N-(3-((4-
nitrophenyl)sulfonamido)propyl)-1-phenylcycloprop-2-ene-1-
carboxamide (129g) (26.2 mg, 0.053 mmol, 1 equiv.) and freshly-ground 
potassium hydroxide (6.0 mg, 0.107 mmol, 2 equiv.) The reaction mixture 
was stirred for 24 hours at 50 °C. The target compound was obtained as a white crystalline 
solid (8.2 mg, 0.016 mmol, 31%); Rf = 0.26 (hexanes:EtOAc:MeOH, 6:3:1) mp 145 °C 
(decomposed); 1H NMR (500 MHz, CDCl3) δ 8.43 (d, J = 8.5 Hz, 2H), 8.05 (d, J = 8.5 Hz, 
2H), 7.36 – 7.18 (m, 8H), 7.17 – 7.08 (m, 2H), 5.25 (d, J = 14.8 Hz, 1H), 4.22 – 4.16 (m, 
1H), 4.12 (d, J = 14.8 Hz, 1H), 3.72 (dd, J = 15.7, 11.0 Hz, 1H), 3.10 (dd, J = 15.7, 6.2 Hz, 
1H), 2.91 – 2.77 (m, 1H), 2.77 – 2.63 (m, 2H), 2.02 – 1.91 (m, 1H), 1.63 – 1.57 (m, 1H), 
1.39 (t, J = 6.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 169.0, 150.6, 143.9, 138.2, 137.3, 
129.1 (+), 129.0 (+), 128.8 (+), 128.5 (+), 127.7 (+), 127.5 (+), 125.5 (+), 124.7 (+), 53.6 
(–), 49.6 (–), 46.3, 46.0 (–), 37.0, 28.4 (–), 23.5 (–); FT IR (NaCl, cm-1): 3052, 2926, 2852, 
1701, 1640, 1530, 1446, 1377, 1350, 1163, 853, 737, 700, 609, 591; HRMS (TOF ES): 











diazabicyclo[6.1.0]nonan-7-one (164h): A 5 mL oven-dried v-vial was 
charged with N-benzyl-N-(3-((3,4-
dimethoxyphenyl)sulfonamido)propyl)-1-phenylcycloprop-2-ene-1-
carboxamide (129h) (32.9 mg, 0.063 mmol, 1 equiv.), freshly-ground potassium hydroxide 
(7.1 mg, 0.126 mmol, 2 equiv.), and dry THF (1.3 mL). The reaction mixture was stirred 
overnight (14 h) at 50 °C. The reaction mixture was allowed to cool RT and passed through 
a short plug of silica eluting with EtOAc. Solvent was removed from the resulting solution 
via rotary evaporation. The product was purified by column chromatography on silica gel 
eluting with hexanes:EtOAc:MeOH (6:3:1) to afford the title compound as an inseparable 
mixture of diastereomers (~1:1) as a white solid (29.5 mg, 0.057 mmol, 90%); Rf = 0.25 
(hexanes:EtOAc:MeOH, 6:3:1); mp 92-103 °C; 1H NMR (500 MHz, CDCl3) δ 7.27 – 7.10 
(m, 20H), 5.21 (dd, J = 22.0, 14.7 Hz, 2H), 4.10 (ddt, J = 19.2, 16.6, 3.6 Hz, 2H), 4.03 (d, 
J = 14.8 Hz, 1H), 3.97 (d, J = 14.8 Hz, 1H), 3.70 (ddd, J = 15.5, 10.9, 4.2 Hz, 2H), 3.41 (d, 
J = 14.6 Hz, 1H), 3.33 (d, J = 14.5 Hz, 1H), 3.27 (dd, J = 8.2, 5.3 Hz, 1H), 3.17 (dd, J = 
8.3, 5.4 Hz, 1H), 3.09 (ddd, J = 15.0, 12.4, 3.1 Hz, 1H), 3.06 – 2.97 (m, 3H), 2.90 (d, J = 
14.6 Hz, 1H), 2.76 (d, J = 14.6 Hz, 1H), 2.67 (dd, J = 6.7, 5.3 Hz, 1H), 2.55 (dd, J = 7.0, 
5.4 Hz, 1H), 2.47 (dddd, J = 21.6, 14.8, 11.8, 4.0 Hz, 2H), 2.35 (q, J = 4.0 Hz, 1H), 2.32 
(q, J = 4.0 Hz, 1H), 2.06 (q, J = 4.3 Hz, 2H), 2.00 (tq, J = 12.2, 4.4 Hz, 2H), 1.91 (d, J = 
5.2 Hz, 1H), 1.87 (d, J = 5.3 Hz, 1H), 1.62 (dddd, J = 14.0, 9.3, 7.1, 4.7 Hz, 4H), 1.50 
(dddd, J = 11.3, 8.6, 6.4, 3.1 Hz, 2H), 1.42 – 1.33 (m, 4H), 1.09 (s, 3H), 1.07 (s, 3H), 0.85 
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(d, J = 2.6 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 215.8, 215.8, 169.5, 169.3, 138.8, 
138.8, 137.6, 137.5, 129.0 (+), 128.7 (2C, (+)), 128.5 (+), 127.6 (2C, (+)), 127.1 (+), 125.5 
(+), 125.4 (+), 58.8, 58.7, 53.7 (–), 53.1 (–), 49.4 (–), 49.1 (–), 48.4, 48.1, 46.7 (–), 46.6 
(+), 46.3 (+), 46.2 (–), 46.0 (–), 43.0 (+), 42.9 (+), 42.8 (–), 36.7, 36.5, 28.6 (–), 28.3 (–), 
27.1 (2C, (–)), 25.5 (2C, (–)), 23.6 (–), 23.3 (–), 20.2 (+), 20.1 (+), 20.0 (+); FT IR (NaCl, 
cm-1): 3060, 3028, 2961, 1745, 1640, 1496, 1480, 1342, 1052, 757, 699, 562, 526. HRMS 
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Appendix 
A1. Hartree-Fock Computations of Oxocan-2-one 
The ab initio ground state geometry optimization and energy calculations of 
oxocan-2-one were performed using restricted Hartree-Fock employing a as basis set of 6-
311++G(d,p)). 
Energy: -421.891991122 a.u. 
Z-matrix of oxocan-2-one: 
 C                  1.43376569   -0.37089891   -0.04441113 
 C                  0.98518472    0.70421237    0.93409465 
 C                  0.26726831    1.85590377    0.21987702 
 C                 -0.89275971    1.40744519   -0.68181081 
 C                 -1.94312826    0.54516694    0.03598411 
 C                 -1.80041813   -0.96837317   -0.19432286 
 C                 -0.59524293   -1.65212469    0.45100201 
 O                  0.59953969   -1.42953933   -0.24823778 
 O                  2.48711853   -0.26131536   -0.63797200 
 H                  1.90229829    1.11210344    1.42415200 
 H                  0.38681545    0.32534972    1.78565390 
 H                  1.00577699    2.41665684   -0.40379104 
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 H                 -0.11348389    2.57574359    0.98441366 
 H                 -1.38373970    2.33322119   -1.07188643 
 H                 -0.50765766    0.87309877   -1.58086578 
 H                 -1.96690205    0.77545337    1.12578441 
 H                 -2.94957934    0.83841592   -0.35545831 
 H                 -1.81446968   -1.18591074   -1.28893475 
 H                 -2.71861814   -1.45214738    0.22454216 
 H                 -0.76514284   -2.75529879    0.38662630 
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A2 Structure Determination of 164d 
1H and 13C NMR spectra show no evidence of rotational isomers, as is expected 
when rotation around the amide bond is no longer possible. Instead magnetically non-
equivalent signals appear for all aliphatic protons. Each pair of protons on each methylene 
carbon of the propylene chain (C6, C6, C7) are pairs of diastereotopic protons, indicating 
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Below, the aliphatic region of the DEPT-135 (top) and 13C (Compound Pulse 
Decoupled) (bottom) are stacked and confirm the presence of five CH2 groups, two (+) 
signals in DEPT-135 indicating methine or methyl carbons, and one signal which appears 
in the 13C but not in the DEPT indicating a fully substituted carbon – each magnetically 
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HSQC data indicate the presence of the 1,1,2-trisubsituted system of compound 
164d. One-bond C-H interactions exist for carbon C3 (23.9 ppm) with both protons H9 
(2.69 ppm) and H10 (1.36 ppm) with. A one-bond C-H interaction exists for C3 (46.8 ppm) 
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